WHAT IS CLAIMED IS:

1. A method of inhibiting mitogen activated protein kinase-activated protein kinase-2 in a subject in need of such inhibition, the method comprising administering to the subject an anminocyanopyridine MK-2 inhibiting compound, or a pharmaceutically acceptable salt thereof, the compound having the structure:



wherein:

R^1 is selected from the group consisting of -H, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, carboxy C_1-C_4 alkyl, aryl C_1-C_4 alkyl, amino, amino C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 alkylamino, C_1-C_4 alkyl, di-(C_1-C_4 alkyl)amino C_1-C_4 alkyl, C_1-C_4 alkyl-C_1-C_4 alkyl, hydroxy C_1-C_4 alkyl, and aryl C_1-C_4 alkylcarbonyl;

R^2 is selected from the group consisting of -H, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, amino, amino C_1-C_4 alkyl, C_1-C_4 alkylamino, aryl, heteroaryl, heterocyclyl, carboxy, carboxy C_1-C_4 alkyl, C_1-C_4 alkoxy, hydroxy, hydroxy C_1-C_4 alkyl, hydroxy C_1-C_4 alkylamino, hydroxy C_1-C_4 alkoxy, C_1-C_4 alkoxy C_1-C_4 alkyl, C_1-C_4 alkoxy C_1-C_4 alkylamino, amino C_1-C_4 alkylamino, aryl C_1-C_4 alkyl, C_1-C_4 alkylamino C_1-C_4 alkyl, di C_1-C_4 alkylamino C_1-C_4 alkyl, C_1-C_4 alkyl C_1-C_4 alkyl, carboxy C_1-C_4 alkyl, aryl C_1-C_4 alkylcarbonyl, phthaloamino C_1-C_4 alkyl, halo, carbamyl, C_1-C_4 alkylthio, C_1-C_4 alkoxyarylamino, C_1-C_{10} mono- and bicyclic cycloalkyl, wherein aryl, heteroaryl, heterocyclyl, mono- and bicyclic cycloalkyl can be optionally substituted with one or more of the groups selected from

halogen, hydroxy, C_1-C_4 alkoxy, aryloxy, C_2-C_4 alkenyloxy, C_2-C_4 alkynyloxy, C_1-C_4 alkyl, carboxy, carbamyl, C_1-C_4 alkoxycarbonyl, C_1-C_4 alkoxycarbonyl C_1-C_4 alkoxy, carboxy C_1-C_4 alkoxy amino, C_1-C_4 alkylamino, di-C_1-C_4 alkylamino, *N*-C_1-C_4 alkyl-*N*-cyano C_1-C_4 alkylamino, nitro, C_1-C_4 alkylcarbonylamino, cyano, halo C_1-C_4 alkyl, di-halo C_1-C_4 alkyl, tri-halo C_1-C_4 alkyl, hydroxy C_1-C_4 alkoxy, halo C_1-C_4 alkoxy, tri-halo C_1-C_4 alkoxy,



;

R^3 is selected from the group consisting of -H, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, cyano, amino C_1-C_4 alkyl, amino, aryl, wherein the aryl group optionally can be substituted with one or more group selected from halogen, hydroxy, C_1-C_4 alkoxy, C_1-C_4 alkyl, carboxy, C_1-C_4 alkoxycarbonyl, carboxy C_1-C_4 alkoxy, amino, di- C_1-C_4 alkylamino, *N*-C_1-C_4 alkyl-*N*-cyano C_1-C_4 alkylamino, nitro, C_1-C_4 alkylcarbonylamino, cyano, halo C_1-C_4 alkyl, di-halo C_1-C_4 alkyl, tri-halo C_1-C_4 alkyl, halo C_1-C_4 alkoxy, di-halo C_1-C_4 alkoxy, tri-halo C_1-C_4 alkoxy, and

where the R^2 and R^3 groups are such that they optionally join to form a ring system selected from:



;

R^4 is selected from the group consisting of -H, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, hydroxy, C_1-C_4 alkylthio, C_1-C_4 alkoxy, C_1-C_4 alkoxycarbonyl, mercapto, *N*-imidazoylphenyl, , C_1-C_4 isoalkyl, aminofluorobenzhydryl, aryl and heteroaryl, wherein the aryl and heteroaryl groups optionally can be substituted with one or more groups selected from halogen, hydroxy, C_1-C_4 alkoxy, C_1-C_4 alkyl, C_1-C_4 alkylthio, C_1-C_4 alkylsulfonyl, C_1-C_4 alkylsulfinyl, cartoxy, carbamyl, C_1-C_4 alkoxycarbonyl, carboxy C_1-C_4 alkyl, carboxy C_1-C_4 alkoxy, amino, di- C_1-C_4 alkylamino, *N*-C_1-C_4 alkyl-*N*-cyano C_1-C_4 alkylamino, nitro, C_1-C_4 alkylcarbonylamino, cyano, halo C_1-C_4 alkyl, di-halo C_1-C_4 alkyl, tri-halo C_1-C_4 alkyl, halo C_1-C_4 alkoxy, di-halo C_1-C_4 alkoxy, tri-halo C_1-C_4 alkoxy



,



, and



;

wherein the R^3 and R^4 groups are such that they optionally join to form a ring system selected from:


R7
R6
R8
R9
R10
D
E
G
R11
R12

,


R14
R13
R15
R16
R17
R18
R19
R20

,


R22
R21
R24
R23
D
R25
E
R26
G
R27
R28
R29
R30

,


R31
R32
R33
R34

,


R37
R36
R35
R38
D
R39
E
G
R40
R41
R42

,


R43
R44
R45
R46

,


R50
R49
R48
R47
R51
R52
R53
R54
D

,


R56
R57
R55
R58
D
E
R59
G
R60
R62
R61

,


R63
R64
R65
R66
R667
R68
R69
R70

, and


R72
R71
D
R73
E
R74
G
R75
R76

;

D, E and G are each independently selected from carbon, oxygen, sulfur, and nitrogen;

R^5 is selected from the group consisting of -H, and C_1-C_5 alkyl; and

wherein the R^1 and R^5 groups optionally join to form a piperidyl ring or an oxazinyl ring;

R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}, R^{23}, R^{24}, R^{25}, R^{26}, R^{27}, R^{28}, R^{29}, R^{30}, R^{31}, R^{32}, R^{33}, R^{34}, R^{35}, R^{36}, R^{37}, R^{38}, R^{39}, R^{40}, R^{41}, R^{42}, R^{43}, R^{44}, R^{45}, R^{46}, R^{47}, R^{48}, R^{49}, R^{50}, R^{51}, R^{52}, R^{53}, R^{54}, R^{55}, R^{56}, R^{57}, R^{58}, R^{59}, R^{60}, R^{61}, R^{62}, R^{63}, R^{64}, R^{65}, R^{66}, R^{67}, R^{68}, R^{69}, R^{70}, R^{71}, R^{72}, R^{73}, R^{74}, R^{75}, and R^{76} are each optionally present and are each independently selected from the group consisting of -H, C_1-C_4 alkyl, C_2-C_4 alkenyl, C_2-C_4 alkynyl, C_1-C_4 isoalkyl, amino, nitro, hydroxy, C_1-C_4 alkoxy, C_1-C_4 alkenoxy, oxo, carboxy, halo, halo C_1-C_4 alkyl, dihalo C_1-C_4 alkyl, trihalo C_1-C_4 alkyl, cyano, cyano C_1-C_4 alkyl, dicyano C_1-C_4 alkyl, halophenyl, hydroxy C_1-C_4 alkoxy, C_1-C_4 alkoxy C_1-C_4 alkoxy, -(CH_2)-O-(C_6H_4)-O-(CH_3), carboxy C_1-C_4 alkoxy, C_1-C_4 alkylcarboxy C_1-C_4 alkoxy, C_1-C_4 alkoxyamino, C_1-C_4 alkylamino, di C_1-C_4 alkylamino, tri C_1-C_4 alkylamino, amino C_1-C_4 alkoxy, diamino C_1-C_4 alkoxy, C_1-C_4 alkylamino C_1-C_4 alkoxy, di C_1-C_4 alkylamino C_1-C_4 alkoxy, cyano C_1-C_4 alkoxy C_1-C_4 alkyl, -(CH_2)-O-(CF_2)-CHF_2, tetra C_1-C_4 alkoxy C_1-C_4 alkyl, phenyl, benzyl, benzoyl, aryl, *N*-morpholinyl, morpholinyl C_1-C_4 alkoxy, pyrrolidyl C_1-C_4 alkoxy, *N*-pyrrolidyl C_1-C_4 alkoxy, C_1-C_4 alkylcarboxy, carboxy C_1-C_4 alkyl - ethyl ester, pyridyl C_1-C_4 alkyl, pyridyl C_1-C_4 alkoxy, -COO-CH_2-CH_3; and

wherein R^{38} and R^{39} are such that they optionally join to form a ring system of the type selected from:



, and



.

2. The method according to claim 1, wherein the aminocyanopyridine MK-2 inhibiting compound is one having the structure:



wherein:

R^1 is selected from the group consisting of -H, methyl, ethyl, propyl, butyl, -(CH_2)COOH, phenyl, pyridyl, dimethylaminoethyl, methoxyethyl, tetramethylaminoethyl, carboxymethyl, and phenylacetyl;

R^2 is selected from the group consisting of -H, methyl, ethyl, propyl, butyl, amino, phenyl, methoxy, carboxy, carboxymethyl, hydroxyethylamino, propylamino, ethylamino, methylamino, methoxyethyl, ethoxyethylamino, aminoethylamino, benzylamino, dimethylaminoethylamino, phthaloaminoethyl, fluorophenyl, difluorophenyl, chlorophenyl, bromophenyl, furyl, carbamylpyrryl, methyl-1,3-isodiazoyl, 1,3-isodiazoyl, 1,3,4-triazoyl, methoxyphenyl, -$S(CH_3)$, tetramethylaminoethyl, acetylaminophenyl, methoxyphenylamino, carboxyphenyl, carboxy-3-isopyrryl, cyanophenyl, cyclopropyl, phenoxyphenyl, pyridyl, dihydroxybromophenyl, difluoromethoxyphenyl, trifluoromethylphenyl, trifluoromethylfluorophenyl, hydroxyphenyl, methylaminomethyl, methylaminoethyl, thiophyl, pyrryl, aminomethyl,



R^3 is selected from the group consisting of -H, methyl, ethyl, propyl, isopropyl, cyano, aminomethyl, phenyl, fluorophenyl, and amino;

wherein the R^2 and R^3 groups are such that they optionally join to form a ring system selected from:



;

R^4 is selected from the group consisting of -H, methyl, ethyl, propyl, hydroxy, furyl, methylfuryl, methylimidazolyl, phenyl, hydroxyphenyl, carboxyphenyl, pyrazolyl, hydroxy, dihydroxyphenyl, methoxyphenyl, chlorophenyl, bromophenyl, fluorophenyl, dichlorophenyl, dihydroxyborophenyl, thienyl, pyrryl, *N*-methylpyrryl, pyridyl, methylthio, methylsulfonylphenyl, carboethoxyphenyl, methoxy, carbamylphenyl, mercapto, *N*-isoimidazoylphenyl, isopropyl, amino, hydroxynaphthyl, thiazoyl, carboxymethylphenyl, trifluoromethylphenyl, methylphenyl, cyanophenyl, dimethylphenyl, fluorobenzhydryl, methoxyfuryl, aminosulfonylphenyl,





, and



;

wherein the R^3 and R^4 groups are such that they optionally join to form a ring system selected from:


R7
R6
R8
R9
R10
D
E
G
R11
R12

,


R14
R13
R15
R16
R17
R18
R19
R20

,


R22
R21
R24
R23
D
R25
E
R26
G
R27
R28
R29
R30

,


R31
R32
R33
R34

,


R37
R36
R35
R38
D
R39
E
G
R40
R41
R42

,


R43
R44
R45
R46

,


R50
R49
R48
R47
R51
R52
R53
R54
D

,


R56
R57
R55
R58
D
E
R59
G
R60
R62
R61

,


R63
R64
R65
R66
R70
R667
R69
R68

, and


R72
R71
D
R73
E
R74
G
R75
R76

;

D, E and G are each independently selected from the group consisting of carbon, oxygen, sulfur, and nitrogen;

R^5 is selected from the group consisting of -H, and C_1-C_5 alkyl; and

wherein the R^1 and R^5 groups can join to form a piperidyl ring;

R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}, R^{23}, R^{24}, R^{25}, R^{26}, R^{27}, R^{28}, R^{29}, R^{30}, R^{31}, R^{32}, R^{33}, R^{34}, R^{35}, R^{36}, R^{37}, R^{38}, R^{39}, R^{40}, R^{41}, R^{42}, R^{43}, R^{44}, R^{45}, R^{46}, R^{47}, R^{48}, R^{49}, R^{50}, R^{51}, R^{52}, R^{53}, R^{54}, R^{55}, R^{56}, R^{57}, R^{58}, R^{59}, R^{60}, R^{61}, R^{62}, R^{63}, R^{64}, R^{65}, R^{66}, R^{67}, R^{68}, R^{69}, R^{70} R^{71}, R^{72}, R^{73}, R^{74}, R^{75}, and R^{76} are each optionally present and are each independently selected from the group consisting of - H, methyl, ethyl, propyl, butyl, isobutyl, amino, nitro, hydroxy, methoxy, ethoxy, propoxy, 2-propenoxy, oxo, carboxy, bromo, chloro, fluoro, trifluoromethyl, chloromethyl, hydroxymethyl, dicyanomethyl, 2-fluorophenyl, 3-fluorophenyl, hydroxyethoxy, ethoxyethoxy, -(CH_2)-O-(C_6H_4)-O-(CH_3), carboxymethoxy, isopropylcarboxymethoxy, isobutylcarboxymethoxy, methylamino, dimethylamino, aminoethoxy, diaminoethoxy, dimethylaminoethoxy, cyanomethoxymethyl, 2-propenoxymethyl, methoxymethyl, isopropoxymethyl, ethoxymethyl, -(CH_2)-O-(CF_2)-CHF_2, isobutoxymethyl, benzoyl, phenyl, *N*-morpholinyl, morpholinylethoxy, pyrrolidylethoxy, *N*-pyrrolidylethoxy, oxo, ethylcarboxy, carboxymethyl - ethyl ester, pyridylmethyl, 4-pyridylmethoxy, 2-pyridylmethyl, and -COO-CH_2-CH_3; and

wherein R^{38} and R^{39} are such that they can join to form a ring system of the type selected from:


, and


3. The method according to claim 2, wherein the aminocyanopyridine MK-2 inhibiting compound is one wherein:

R^1 is selected from the group consisting of -H, methyl, ethyl, -(CH_2)COOH, and phenyl;

R^2 is selected from the group consisting of -H, methyl, ethyl, amino, phenyl, methoxy, carboxy, hydroxyethylamino, propylamino, ethylamino, methylamino, methoxyethyl, ethoxyethylamino, aminoethylamino, benzylamino, dimethylaminoethylamino, fluorophenyl, difluorophenyl, chlorophenyl, bromophenyl, furyl, carbamylpyrryl, methyl-1,3-isodiazoyl, 1,3-isodiazoyl, 1,3,4-triazoyl, methoxyphenyl, -S(CH_3), acetylaminophenyl, methoxyphenylamino, carboxyphenyl, cyanophenyl, cyclopropyl, phenoxyphenyl, pyridyl, dihydroxybromophenyl, difluoromethoxyphenyl, trifluoromethylphenyl, trifluoromethylfluorophenyl, hydroxyphenyl,


, and


;

R^3 is selected from the group consisting of -H, methyl, ethyl, propyl, isopropyl, cyano, and aminomethyl;

wherein the R^2 and R^3 groups are such that they optionally join to form a ring system selected from:



, and

;

R^4 is selected from the group consisting of -H, methyl, ethyl, propyl, hydroxy, furyl, indolyl, methylfuryl, methylimidazolyl, phenyl, hydroxyphenyl, carboxyphenyl, pyrazolyl, hydroxy, dihydroxyphenyl, methoxyphenyl, chlorophenyl, dichlorophenyl, dihydroxyborophenyl,

thienyl, pyrryl, *N*-methylpyrryl, pyridyl, methylthio, methylsulfonylphenyl, carboethoxyphenyl, methoxy, carbamylphenyl, *N*-isoimidazoylphenyl, amino, hydroxynaphthyl, thiazoyl, carboxymethylphenyl, aminosulfonylphenyl, and



;

wherein the R^3 and R^4 groups are such that they optionally join to form a ring system selected from:



,



,



,



,



, and



;

D, E and G are each independently selected from the group consisting of carbon, oxygen, sulfur, and nitrogen;

R^5 is selected from the group consisting of -H, and C_1-C_5 alkyl;

R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{31}, R^{32}, R^{33}, R^{34}, R^{35}, R^{36}, R^{37}, R^{38}, R^{39}, R^{40}, R^{41}, R^{42}, R^{43}, R^{44}, R^{45}, R^{46}, R^{71}, R^{72}, R^{73}, R^{74}, R^{75}, and R^{76} are each optionally present and are each independently selected from the group consisting of - H, methyl, ethyl, butyl, amino, nitro, hydroxy, methoxy, ethoxy, oxo, 2-propenoxy, carboxy, bromo, chloro, fluoro, trifluoromethyl, chloromethyl, hydroxymethyl, dicyanomethyl, hydroxyethoxy, ethoxyethoxy, -(CH_2)-O-(C_6H_4)-O-(CH_3), carboxymethoxy, isopropylcarboxymethoxy, methylamino, dimethylamino, aminoethoxy, diaminoethoxy, cyanomethoxymethyl, methoxymethyl, isopropoxymethyl, ethoxymethyl, -(CH_2)-O-(CF_2)-CHF_2, isobutoxymethyl, phenyl, morpholinylethoxy, pyrrolidylethoxy, *N*-pyrrolidylethoxy, and pyridylmethyl, and

wherein R^{38} and R^{39} are such that they optionally join to form a ring system of the type selected from:


, and


4. The method according to claim 2, wherein the aminocyanopyridine MK-2 inhibiting compound is one wherein:

R^1 is selected from the group consisting of -H, methyl, and ethyl;

R^2 is selected from the group consisting of -H, methyl, amino, phenyl, methoxy, hydroxyethylamino, propylamino, ethylamino, methylamino, methoxyethyl, ethoxyethylamino, aminoethylamino, benzylamino, dimethylaminoethylamino, fluorophenyl, difluorophenyl, chlorophenyl, bromophenyl, furyl, carbamylpyrryl, methyl-1,3-isodiazoyl, 1,3-isodiazoyl, 1,3,4-triazoyl, methoxyphenyl, -S(CH_3), acetylaminophenyl, methoxyphenylamino, carboxyphenyl, cyanophenyl, cyclopropyl,

phenoxyphenyl, pyridyl, dihydroxybromophenyl, difluoromethoxyphenyl, and



;

R^3 is selected from the group consisting of -H, methyl, ethyl, propyl, isopropyl, and cyano;

wherein the R^2 and R^3 groups are such that they optionally join to form a ring system selected from:



, and

;

R^4 is selected from the group consisting of -H, methyl, ethyl, propyl, hydroxy, furyl, indolyl, methylfuryl, methylimidazolyl, phenyl, hydroxyphenyl, carboxyphenyl, pyrazolyl, hydroxy, dihydroxyphenyl, methoxyphenyl, chlorophenyl, dichlorophenyl, dihydroxyborophenyl, thienyl, pyrryl, *N*-methylpyrryl, pyridyl, methylthio, methylsulfonylphenyl, carboethoxyphenyl, methoxy, carbamylphenyl, amino, and aminosulfonylphenyl;

wherein the R^3 and R^4 groups are such that they optionally join to form a ring system selected from:




, and

;

D, E and G are each independently selected from the group consisting of carbon, oxygen, sulfur, and nitrogen;

R^5 is -H;

R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{35}, R^{36}, R^{37}, R^{38}, R^{39}, R^{40}, R^{41}, R^{42}, R^{71}, R^{72}, R^{73}, R^{74}, R^{75}, and R^{76} are each optionally present and are each independently selected from the group consisting of - H, methyl, ethyl, butyl, amino, nitro, hydroxy, methoxy, ethoxy, oxo, 2-propenoxy, carboxy, bromo, fluoro, trifluoromethyl, chloromethyl, dicyanomethyl, hydroxyethoxy, ethoxyethoxy, -(CH_2)-O-(C_6H_4)-O-(CH_3), carboxymethoxy, isopropylcarboxymethoxy, methylamino, dimethylamino, aminoethoxy, diaminoethoxy, phenyl, morpholinylethoxy, pyrrolidylethoxy, *N*-pyrrolidylethoxy, and pyridylmethyl, and

wherein R^{38} and R^{39} are such that they optionally join to form a ring system consisting of:



5. The method according to claim 2, wherein the aminocyanopyridine MK-2 inhibiting compound is one wherein:

R^1 is selected from the group consisting of -H, methyl, and ethyl;

R^2 is selected from the group consisting of -H, methyl, amino, phenyl, methoxy, hydroxyethylamino, propylamino, ethylamino, methylamino, methoxyethyl, ethoxyethylamino, aminoethylamino, benzylamino, dimethylaminoethylamino, fluorophenyl, difluorophenyl, chlorophenyl, bromophenyl, furyl, carbamylpyrryl, methyl-1,3-isodiazoyl, 1,3-isodiazoyl, 1,3,4-triazoyl, methoxyphenyl, -S(CH_3), acetylaminophenyl, methoxyphenylamino, carboxyphenyl, and


;

R^3 is selected from the group consisting of -H, methyl, ethyl, propyl, and isopropyl;

wherein the R^2 and R^3 groups are such that they optionally join to form a ring system selected from:


;

R^4 is selected from the group consisting of -H, methyl, ethyl, propyl, furyl, indolyl, methylfuryl, methylimidazolyl, phenyl, hydroxyphenyl, carboxyphenyl, pyrazolyl, hydroxy, dihydroxyphenyl, methoxyphenyl, chlorophenyl, dichlorophenyl, dihydroxyborophenyl, thienyl, pyrryl, *N*-methylpyrryl, pyridyl, methylthio, methylsulfonylphenyl, carboethoxyphenyl, and aminosulfonylphenyl;

wherein the R^3 and R^4 groups are such that they optionally join to form a ring system selected from:





, and



;

D, E and G are each independently selected from the group consisting of carbon, oxygen, sulfur, and nitrogen;

R^5 is -H;

R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{35}, R^{36}, R^{37}, R^{38}, R^{39}, R^{40}, R^{41}, R^{42}, R^{71}, R^{72}, R^{73}, R^{74}, R^{75}, and R^{76} are each optionally present and are each independently selected from the group consisting of - H, methyl, ethyl, butyl, amino, nitro, hydroxy, methoxy, ethoxy, oxo, 2-propenoxy, carboxy, bromo, fluoro, trifluoromethyl, chloromethyl, dicyanomethyl, hydroxyethoxy, ethoxyethoxy, carboxymethoxy, isopropylcarboxymethoxy, methylamino, dimethylamino, aminoethoxy, diaminoethoxy, morpholinylethoxy, pyrrolidylethoxy, *N*-pyrrolidylethoxy, and pyridylmethyl, and

wherein R^{38} and R^{39} are such that they optionally join to form a ring system consisting of:



6. The method according to claim 2, wherein the aminocyanopyridine MK-2 inhibiting compound is one wherein:

R^1 is -H;

R^2 is selected from the group consisting of amino, phenyl, fluorophenyl, difluorophenyl, furyl, carbamylpyrryl, methyl-1,3-isodiazoyl, 1,3-isodiazoyl, 1,3,4-triazoyl, methoxyphenyl, acetylaminophenyl, methoxyphenylamino, and carboxyphenyl;

R^3 is selected from the group consisting of -H, methyl, ethyl, and propyl;

R^4 is selected from the group consisting of methyl, ethyl, propyl, furyl, phenyl, hydroxyphenyl, carboxyphenyl, pyrazolyl, hydroxy, dihydroxyphenyl, methoxyphenyl, chlorophenyl, dihydroxyborophenyl, and aminosulfonylphenyl;

wherein the R^3 and R^4 groups are such that they optionally join to form a ring system selected from:



,



, and



;

D, E and G are each independently selected from the group consisting of carbon, oxygen, sulfur, and nitrogen;

R^5 is -H;

R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{35}, R^{36}, R^{37}, R^{38}, R^{39}, R^{40}, R^{41}, R^{42}, R^{71}, R^{72}, R^{73}, R^{74}, R^{75}, and R^{76} are each optionally present and are each independently selected from the group consisting of - H, amino, nitro, hydroxy, methoxy, ethoxy, oxo, 2-propenoxy, carboxy, bromo, fluoro, trifluoromethyl, chloromethyl, dicyanomethyl, hydroxyethoxy, ethoxyethoxy, carboxymethoxy, isopropylcarboxymethoxy, methylamino, dimethylamino, aminoethoxy, diaminoethoxy, morpholinylethoxy, pyrrolidylethoxy, and pyridylmethyl, and

wherein R^{38} and R^{39} are such that they optionally join to form a ring system consisting of:



7. The method according to claim 2, wherein the aminocyanopyridine MK-2 inhibiting compound comprises at least one compound that is selected from the group consisting of:
2-amino-4-(2-fluorophenyl)-6,8-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
2-amino-4-(2-furyl)-6,7-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
2-amino-4-(2,3-difluorophenyl)-6,7-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
8-amino-6-(2-furyl)-4,5-dihydro-1H-pyrazolo[4,3-h]quinoline-7-carbonitrile,
2-amino-3-cyano-4-(2-furyl)-5,6-dihydrobenzo[h]quinoline-8-carboxylic acid,
4-[2-amino-3-cyano-6-(2-furyl)pyridin-4-yl]-1H-pyrrole-2-carboxamide,
2-amino-4-phenyl-6,8-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
2-amino-6-(2-furyl)-4-(1-methyl-1H-imidazol-4-yl)nicotinonitrile,

8-amino-6-(2-furyl)-4,5-dihydro-1H-pyrazolo[4,3-h]quinoline-7-carbonitrile,
2-amino-4-(2-furyl)-8-hydroxy-5,6-dihydrobenzo[h]quinoline-3-carbonitrile,
2-amino-4-(2,6-difluorophenyl)-6,7-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
2-amino-6-(4-hydroxyphenyl)-4-(1H-imidazol-5-yl)nicotinonitrile,
2-amino-4-(2-fluorophenyl)-6-(2-furyl)nicotinonitrile, 2-amino-4-(2-fluorophenyl)-6-(2-furyl)nicotinonitrile,
2-amino-4-(2-fluorophenyl)-5,6-dihydrobenzo[h]quinoline-3-carbonitrile,
4-[6-amino-5-cyano-4-(2-furyl)pyridin-2-yl]benzoic acid,
2-amino-6-(2-furyl)-4-(1H-imidazol-5-yl)nicotinonitrile,
2-amino-4-(2-furyl)-6-(1H-pyrazol-3-yl)nicotinonitrile,
2-amino-3-cyano-4-(4H-1,2,4-triazol-3-yl)-5,6-dihydrobenzo[h]quinoline-8-carboxylic acid,
2-amino-6-(3-hydroxyphenyl)-4-(1H-imidazol-5-yl)nicotinonitrile,
2-amino-6-(2-furyl)-4-(1H-imidazol-4-yl)nicotinonitrile,
2-amino-4-(2,4-difluorophenyl)-6,7-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
4,6-diamino-2-(trifluoromethyl)-2,3-dihydrofuro[2,3-b]pyridine-5-carbonitrile,
2-amino-4-(2-furyl)-6,8-dihydro-5H-pyrrolo[3,4-h]quinoline-3-carbonitrile,
4-[6-amino-5-cyano-4-(2-fluorophenyl)pyridin-2-yl]benzoic acid,
2-amino-4-(2-furyl)-5,6-dihydro-1,8-phenanthroline-3-carbonitrile,
2-amino-6-(3,4-dihydroxyphenyl)-4-(2-fluorophenyl)nicotinonitrile,
2-amino-4-(1-methyl-1H-imidazol-4-yl)-6-phenylnicotinonitrile,
2-amino-4-(2-furyl)-6-(1H-pyrazol-3-yl)nicotinonitrile,
4-[6-amino-5-cyano-4-(1H-imidazol-5-yl)pyridin-2-yl]benzoic acid,
2-amino-4-(3-fluorophenyl)-6,8-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
2-amino-6-(3,4-dihydroxyphenyl)-4-(2-fluorophenyl)nicotinonitrile,
N-{4-[6-amino-5-cyano-4-(2-furyl)pyridin-2-yl]phenyl}methanesulfonamide,
2-amino-4-(2-furyl)-6,7-dihydro-5H-pyrrolo[2,3-h]quinoline-3-carbonitrile,
2-amino-4-(1H-imidazol-5-yl)-6-phenylnicotinonitrile,

2-amino-4-(2-furyl)-5,6-dihydrobenzo[h]quinoline-3-carbonitrile,
2-amino-4-(1H-imidazol-5-yl)-6-(4-methoxyphenyl)nicotinonitrile,
2-amino-6-(3-chlorophenyl)-4-(1H-imidazol-5-yl)nicotinonitrile,
2-amino-4-(2-furyl)-6-(1H-pyrazol-4-yl)nicotinonitrile,
2-amino-4-(4-methoxyphenyl)-6,7-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
2-amino-4-(2,5-difluorophenyl)-6,7-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
2-amino-4-(4-fluorophenyl)-6,8-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
2-amino-4-(4H-1,2,4-triazol-3-yl)-5,6-dihydrobenzo[h]quinoline-3-carbonitrile,
4,6-diamino-2-(chloromethyl)-2,3-dihydrofuro[2,3-b]pyridine-5-carbonitrile,
2-amino-4-(1H-imidazol-4-yl)-6-phenylnicotinonitrile,
4-[6-amino-5-cyano-4-(2-furyl)pyridin-2-yl]benzenesulfonamide,
4-[6-amino-5-cyano-4-(2-furyl)pyridin-2-yl]phenylboronic acid,
2-amino-6-(4-methoxyphenyl)-4-(4H-1,2,4-triazol-3-yl)nicotinonitrile,
2-amino-4-(2-fluorophenyl)-6-(3-furyl)nicotinonitrile,
2-amino-6-(2-furyl)-4-(methylthio)nicotinonitrile,
2-amino-4-(2-fluorophenyl)-6-(3-hydroxyphenyl)nicotinonitrile,
8-amino-6-(2-furyl)-4,5-dihydro-2H-pyrazolo[4,3-h]quinoline-7-carbonitrile,
2-amino-4-(2-bromophenyl)-6-(2-furyl)nicotinonitrile,
2-amino-4-(2-fluorophenyl)-6-(4-hydroxyphenyl)nicotinonitrile,
2-amino-4-phenyl-6-thien-2-ylnicotinonitrile,
2-amino-4-(3-methoxyphenyl)-6,7-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
2-amino-4-(2-furyl)-7-methyl-6,7-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
2-amino-4-(2-fluorophenyl)-6-(1H-pyrrol-2-yl)nicotinonitrile,
2-amino-4-(2-furyl)-5-methyl-6,8-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
2-amino-4-(2-furyl)-6-(1-methyl-1H-pyrrol-3-yl)nicotinonitrile,

3-amino-5,6,7,8-tetrahydroisoquinoline-4-carbonitrile,
N-[4-(2-amino-3-cyano-6,7-dihydro-5H-pyrazolo[3,4-h]quinolin-4-yl)phenyl]acetamide,
6-amino-4-[(4-methoxyphenyl)amino]-2-(trifluoromethyl)-2,3-dihydrofuro[2,3-b]pyridine-5-carbonitrile,
4-[6-amino-5-cyano-4-(2-furyl)pyridin-2-yl]-*N*-(tert-butyl)benzenesulfonamide,
4,6-diamino-2-ethyl-2,3-dihydrofuro[2,3-b]pyridine-5-carbonitrile,
6-amino-4-(2-furyl)-2,4'-bipyridine-5-carbonitrile, 2,4-diamino-6-(methylthio)nicotinonitrile,
3-(2-amino-3-cyano-6,7-dihydro-5H-pyrazolo[3,4-h]quinolin-4-yl)benzoic acid,
2-amino-6-(4-chlorophenyl)-4-(1H-imidazol-5-yl)nicotinonitrile,
2-amino-4-(1,3-benzodioxol-4-yl)-6,7-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
4,6-diamino-2-methyl-2,3-dihydrofuro[2,3-b]pyridine-5-carbonitrile,
2-amino-4-(1H-imidazol-5-yl)-6-[4-(methylsulfonyl)phenyl]nicotinonitrile,
2,4-diaminoquinoline-3-carbonitrile,
2,8-diamino-4-(2-furyl)-5,6-dihydrobenzo[h]quinoline-3-carbonitrile,
2-amino-4,6-di(2-furyl)nicotinonitrile,
4,6-diamino-2-butyl-2,3-dihydrofuro[2,3-b]pyridine-5-carbonitrile,
ethyl 4-[6-amino-5-cyano-4-(1H-imidazol-5-yl)pyridin-2-yl]benzoate,
2,4-diamino-6-methoxynicotinonitrile,
2-amino-4-methylnicotinonitrile,
2-amino-4-(4-cyanophenyl)-6,7-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
2-amino-4-cyclopropyl-6-methylnicotinonitrile,
2-amino-4-(2-furyl)-6-(1-methyl-1H-pyrrol-2-yl)nicotinonitrile,
2-amino-4-(2-chlorophenyl)-6,7-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
2-amino-6-(2-furyl)-4-(4-phenoxyphenyl)nicotinonitrile,

2-amino-4-pyridin-3-yl-6,8-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
2-amino-6-{[2-(4-chlorophenyl)-2-oxoethyl]thio}-4-(2-furyl)pyridine-3,5-dicarbonitrile,
4-[2-amino-3-cyano-6-(2-furyl)pyridin-4-yl]phenylboronic acid,
2-amino-6-(3-chlorophenyl)-4-(1H-imidazol-4-yl)nicotinonitrile,
4-(6-amino-5-cyano-4-phenylpyridin-2-yl)-*N*-(tert-butyl)benzenesulfonamide,
2-amino-4-methoxynicotinonitrile,
4-[2-amino-3-cyano-6-(2-furyl)pyridin-4-yl]benzoic acid,
4,6-diamino-2-[(4-methoxyphenoxy)methyl]-2,3-dihydrofuro[2,3-b]pyridine-5-carbonitrile,
2-amino-4-(2-fluorophenyl)-6-(4-methoxyphenyl)nicotinonitrile,
4-[6-amino-5-cyano-4-(2-fluorophenyl)pyridin-2-yl]-*N*-(tert-butyl)benzenesulfonamide,
(2,4-diamino-3-cyano-5H-chromeno[2,3-b]pyridin-9-yl)oxy]acetic acid,
3-pyridinecarbonitrile,
2-amino-4-methylm-2-amino-6-(2-furyl)nicotinonitrile,
2-amino-4-(2-furyl)-6-(3-hydroxyphenyl)nicotinonitrile,
4-[6-amino-5-cyano-4-(2-furyl)pyridin-2-yl]benzamide,
2-amino-4-(2-furyl)-7-hydroxy-5,6-dihydrobenzo[h]quinoline-3-carbonitrile,
2-amino-4-(2-furyl)-6-(1H-indol-3-yl)nicotinonitrile,
2-amino-4-pyridin-4-yl-6,8-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
2-amino-4-(3-fluorophenyl)-6-(4-hydroxyphenyl)nicotinonitrile,
2-amino-4-[2-(difluoromethoxy)phenyl]-6,7-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
2-amino-4-(2-furyl)-6-thien-3-ylnicotinonitrile,
2-amino-4-(3-fluorophenyl)-6-(4-methoxyphenyl)nicotinonitrile,
2-[2-amino-3-cyano-6-(2-furyl)pyridin-4-yl]phenylboronic acid,
2,4-diamino-6-propylpyridine-3,5-dicarbonitrile,

4,6-diamino-2-[(prop-2-ynyloxy)methyl]-2,3-dihydrofuro[2,3-b]pyridine-5-carbonitrile,
4,6-diamino-2-(hydroxymethyl)-2,3-dihydrofuro[2,3-b]pyridine-5-carbonitrile,
2-amino-6-(2-furyl)-4-[4-(trifluoromethyl)phenyl]nicotinonitrile,
5-amino-7-methylthieno[3,2-b]pyridine-6-carbonitrile,
2-amino-4-(2-furyl)-5,5-dimethyl-6,8-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
N-[3-cyano-4-(2-fluorophenyl)-6-(2-furyl)pyridin-2-yl]glycine,
2-[(allyloxy)methyl]-4,6-diamino-2,3-dihydrofuro[2,3-b]pyridine-5-carbonitrile,
2-amino-4-(2-furyl)-6-methyl-5,6-dihydrobenzo[h]quinoline-3-carbonitrile,
4,6-diamino-2-(methoxymethyl)-2,3-dihydrofuro[2,3-b]pyridine-5-carbonitrile,
2-amino-4-(2-furyl)-6-(1H-indol-3-yl)nicotinonitrile,
2-amino-4-(2-furyl)-6-[4-(1H-imidazol-1-yl)phenyl]nicotinonitrile,
2-amino-4-(2-furyl)-6-(4-hydroxyphenyl)nicotinonitrile,
2-amino-4-(2-furyl)-5,6,7,8-tetrahydro-5,8-methanoquinoline-3-carbonitrile,
4,6-diamino-2-(isopropoxymethyl)-2,3-dihydrofuro[2,3-b]pyridine-5-carbonitrile,
3-[6-amino-5-cyano-4-(2-furyl)pyridin-2-yl]phenylboronic acid,
4,6-diamino-2-(ethoxymethyl)-2,3-dihydrofuro[2,3-b]pyridine-5-carbonitrile,
2-amino-4-(4-bromophenyl)-6-(2-furyl)nicotinonitrile,
4,6-diamino-2-[(1,1,2,2-tetrafluoroethoxy)methyl]-2,3-dihydrofuro[2,3-b]pyridine-5-carbonitrile,
2-amino-4-[2-fluoro-4-(trifluoromethyl)phenyl]-6-(2-furyl)nicotinonitrile,
2-amino-4-(2-methoxyphenyl)-6,8-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
2-amino-4-(2-fluorophenyl)-5-methyl-6,8-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
3,6-diamino-4-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carbonitrile,
6-amino-4-(2-furyl)-2,2'-bipyridine-5-carbonitrile,

2-amino-4-(2-furyl)-6-(8-hydroxy-1-naphthyl)nicotinonitrile,
4-(2-amino-3-cyano-6,7-dihydro-5H-pyrazolo[3,4-h]quinolin-4-yl)benzoic acid,
2-amino-6-(3,4-dichlorophenyl)-4-(2-furyl)nicotinonitrile,
2-amino-4-(2-furyl)-6-(10H-phenothiazin-2-yl)nicotinonitrile,
sodium 2-amino-3-cyano-4-quinolinecarboxylate,
2-anilino-4-(2-fluorophenyl)-6-(2-furyl)nicotinonitrile,
2-amino-4-(3-fluorophenyl)-6-(2-furyl)nicotinonitrile,
2-amino-4-(4-fluorophenyl)-6-(2-furyl)nicotinonitrile,
4,6-diamino-2-(tert-butoxymethyl)-2,3-dihydrofuro[2,3-b]pyridine-5-carbonitrile,
2-amino-4-(2-furyl)-6-(1,3-thiazol-2-yl)nicotinonitrile,
4-(2-fluorophenyl)-6-(2-furyl)-2-piperidin-1-ylnicotinonitrile,
2-amino-6-(4-chlorophenyl)-4-(2-furyl)nicotinonitrile,
2-amino-6-(4-hydroxyphenyl)-4-(2-methoxyphenyl)nicotinonitrile,
2-amino-6-(2-furyl)-4-(2-hydroxyphenyl)nicotinonitrile,
methyl 3-(2-amino-3-cyano-6,7-dihydro-5H-pyrazolo[3,4-h]quinolin-4-yl)benzoate,
2-amino-4-(2-chlorophenyl)-6-(5-methyl-2-furyl)nicotinonitrile,
3,6-diamino-2-benzoylthieno[2,3-b]pyridine-5-carbonitrile,
methyl 4-[6-amino-5-cyano-4-(2-furyl)pyridin-2-yl]benzoate,
2-aminonicotinonitrile,
2-amino-4-(2-furyl)-8-{[2-(trimethylsilyl)ethoxy]methyl}-6,8-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
3-amino-5H-pyrido[4,3-b]indole-4-carbonitrile,
2-(2-amino-3-cyano-6,7-dihydro-5H-pyrazolo[3,4-h]quinolin-4-yl)benzoic acid,
2-amino-6-(4-methoxyphenyl)-4-phenylnicotinonitrile,
2-amino-4-(2-furyl)-5,6,7,8-tetrahydroquinoline-3-carbonitrile,
2-amino-4-(2-furyl)-6-isobutylnicotinonitrile,
2-amino-6-benzyl-4-(2-furyl)nicotinonitrile,
2-amino-4-(2-furyl)-6-methyl-5-phenylnicotinonitrile,

2-amino-4-(2-furyl)-6-[4-(trifluoromethoxy)phenyl]nicotinonitrile,
2-amino-4-(2-furyl)-6-propyl-5,6,7,8-tetrahydro-1,6-naphthyridine-3-carbonitrile,
2-amino-4-(2-furyl)benzo[h]quinoline-3-carbonitrile,
2-amino-6-(4-methoxyphenyl)-4-thien-2-ylnicotinonitrile,
2-amino-4-(2-fluorophenyl)-6-tetrahydrofuran-2-ylnicotinonitrile,
ethyl 6-amino-5-cyano-4-(2-furyl)pyridine-2-carboxylate,
2-amino-4-(2-furyl)-9-methoxy-5,6-dihydrobenzo[h]quinoline-3-carbonitrile,
2-amino-4-(2-furyl)-8-methoxy-5,6-dihydrobenzo[h]quinoline-3-carbonitrile,
2-amino-4-(2-furyl)-8,9-dimethoxy-5,6-dihydrobenzo[h]quinoline-3-carbonitrile,
2-amino-4-(2-furyl)-7-methoxy-5,6-dihydrobenzo[h]quinoline-3-carbonitrile,
2-amino-4-(2-furyl)-7,9-dimethyl-5,6-dihydrobenzo[h]quinoline-3-carbonitrile,
ethyl 4-[6-amino-5-cyano-4-(2-furyl)pyridin-2-yl]benzoate,
2-amino-6-(3-bromophenyl)-4-(2-furyl)nicotinonitrile,
2-amino-4-(2-furyl)-6-[4-(trifluoromethyl)phenyl]nicotinonitrile,
2-amino-4-(2-furyl)-6-[3-(trifluoromethyl)phenyl]nicotinonitrile,
2-amino-4-(2-furyl)-6-[4-(methylsulfonyl)phenyl]nicotinonitrile,
4,6-diamino-2-(phenoxymethyl)-2,3-dihydrofuro[2,3-b]pyridine-5-carbonitrile,
4,6-diamino-3-phenyl-2,3-dihydrofuro[2,3-b]pyridine-5-carbonitrile,
4,6-diamino-3-vinyl-2,3-dihydrofuro[2,3-b]pyridine-5-carbonitrile,
2-amino-4-(2-fluorophenyl)-5-methyl-6,8-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
3-amino-1-methyl-5,6,7,8-tetrahydroisoquinoline-4-carbonitrile,
2-amino-4-(2-fluorophenyl)-5,5-dimethyl-6,8-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
2-amino-4-(2-fluorophenyl)-6-(3-hydroxyphenyl)nicotinonitrile,
2-amino-4-[2-(difluoromethoxy)phenyl]-6,7-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
2-(benzylamino)-4-(2-fluorophenyl)-6-(2-furyl)nicotinonitrile,

2-amino-4-(2-furyl)-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-b]pyridine-3-carbonitrile,
2-amino-4-(2-furyl)-5H-indeno[1,2-b]pyridine-3-carbonitrile,
3-amino-1-methyl-5,6,7,8-tetrahydroisoquinoline-4-carbonitrile,
2-amino-4-(2-fluorophenyl)-6-(3-hydroxyphenyl)nicotinonitrile,
2-amino-4-(2-thienyl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile,
2-amino-4-(3-fluorophenyl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile,
2-(1-piperidinyl)-6-(2-thienyl)-4-(trifluoromethyl)nicotinonitrile,
2-(dimethylamino)-6-(2-thienyl)-4-(trifluoromethyl)nicotinonitrile,
3-Quinolinecarbonitrile,
2-amino-4-methyl- or 2-amino-4-methyl-3-quinolinecarbonitrile,
2-amino-4-(4-methoxyphenyl)-6-(2-thienyl)nicotinonitrile,
2-amino-6-cyclopropyl-4-(2-methoxyphenyl)nicotinonitrile,
2-amino-4-(2-fluorophenyl)-6-phenylnicotinonitrile,
(4bS,8aR)-2,4-diamino-4b,5,6,7,8,8a-hexahydro[1]benzofuro[2,3-b]pyridine-3-carbonitrile,
2-amino-4-(2-fluorophenyl)-5,5-dimethyl-6,8-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
2-amino-4-(2-furyl)-5-phenyl-6,8-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
3-amino-1,6-dimethyl-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile,
3-amino-1,7-dimethyl-5,6,7,8-tetrahydro-2,7-naphthyridine-4-carbonitrile,
2-amino-4-(2-fluorophenyl)-5-phenyl-6,8-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
2-amino-4-(2-fluorophenyl)-5-phenyl-6,8-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
4,6-diamino-2-(morpholin-4-ylmethyl)-2,3-dihydrofuro[2,3-b]pyridine-5-carbonitrile,
ethyl (4,6-diamino-5-cyano-2-oxo-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-1-yl)acetate,
2-amino-4-(2-methoxyphenyl)-6-(5-methyl-2-furyl)nicotinonitrile,
2-amino-6-methyl-4-(4-nitrophenyl)nicotinonitrile,

2-amino-4-(3,4-dimethoxyphenyl)-6-(5-methyl-2-furyl)nicotinonitrile,
2,4-diamino-6-[(4-methoxyphenyl)thio]nicotinonitrile,
4,6-diamino-2-(phenoxymethyl)-2,3-dihydrofuro[2,3-b]pyridine-5-carbonitrile,
4,6-diamino-3-phenyl-2,3-dihydrofuro[2,3-b]pyridine-5-carbonitrile,
4,6-diamino-2-[(2-methylphenoxy)methyl]-2,3-dihydrofuro[2,3-b]pyridine-5-carbonitrile,
2-amino-4-(2-furyl)-6-(4-methoxyphenyl)nicotinonitrile,
2-amino-4-(3-fluorophenyl)-5,6-dihydrobenzo[h]quinoline-3-carbonitrile,
2-amino-4-(4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[b]pyridine-3-carbonitrile,
2-amino-9-ethyl-9H-pyrido[2,3-b]indole-3-carbonitrile,
2-amino-6-isobutyl-4-(4-methylphenyl)nicotinonitrile,
1-(2-furyl)-3-[(3-hydroxypropyl)amino]-5,6,7,8-tetrahydroisoquinoline-4-carbonitrile,
2-azepan-1-yl-6-(4-fluorophenyl)-4-phenylnicotinonitrile,
2-amino-6-tert-butyl-4-(4-methylphenyl)nicotinonitrile,
2-amino-4-(4-bromophenyl)-6-methylnicotinonitrile,
2-amino-4-thien-2-yl-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine-3-carbonitrile,
2-amino-4-(4-chlorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine-3-carbonitrile,
2-(allylamino)-5-amino-7-(4-bromophenyl)thieno[3,2-b]pyridine-3,6-dicarbonitrile,
2-amino-4-pyridin-3-yl-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine-3-carbonitrile,
2-amino-4-(4-bromophenyl)-6-tert-butylnicotinonitrile,
1-(2-furyl)-3-morpholin-4-yl-5,6,7,8-tetrahydroisoquinoline-4-carbonitrile,
2-amino-4-(4-methylphenyl)-6,7-dihydro-5H-cyclopenta[b]pyridine-3-carbonitrile,
2-amino-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile,
2-amino-6-isobutyl-4-(4-methoxyphenyl)nicotinonitrile,

4,6-diamino-2-oxo-1-phenyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile,
2-amino-4-(2-methoxyphenyl)-5,6-dimethylnicotinonitrile,
2-(dimethylamino)-4-(2-fluorophenyl)-6-(2-furyl)nicotinonitrile,
2-(dimethylamino)-4-(2-fluorophenyl)-6-(2-furyl)nicotinonitrile,
4-(2-fluorophenyl)-6-(2-furyl)-2-(methylamino)nicotinonitrile,
4-(2-fluorophenyl)-6-(2-furyl)-2-morpholin-4-ylnicotinonitrile,
tert-butyl *N*-[3-cyano-4-(2-fluorophenyl)-6-(2-furyl)pyridin-2-yl]glycinate,
2-(ethylamino)-4-(2-fluorophenyl)-6-(2-furyl)nicotinonitrile,
ethyl 4-[6-amino-5-cyano-4-(2-fluorophenyl)pyridin-2-yl]benzoate,
2-amino-6-(2-fluorophenyl)-4-(3-furyl)nicotinonitrile,
6-amino-4-(2-fluorophenyl)-2,2'-bipyridine-5-carbonitrile,
2-amino-4-(2-fluorophenyl)-6-thien-2-ylnicotinonitrile,
ethyl 6-amino-5-cyano-4-(2-fluorophenyl)pyridine-2-carboxylate,
2-amino-6-(2-furyl)-4-phenylnicotinonitrile,
ethyl 2-amino-3-cyano-4-(2-furyl)-5,6,7,8-tetrahydroquinoline-6-carboxylate,
2-amino-4-(2-furyl)-6-(4-hydroxyphenyl)-5-methylnicotinonitrile,
2-amino-4-(2-furyl)-6-(4-methoxyphenyl)-5-methylnicotinonitrile,
2-amino-6-(4-fluorophenyl)-4-(2-furyl)-5-methylnicotinonitrile,
2-amino-4-(2-furyl)-5,6-diphenylnicotinonitrile,
2-amino-4-(2-furyl)-5-methyl-6-phenylnicotinonitrile,
2-amino-6-(3,4-dimethylphenyl)-4-(2-furyl)nicotinonitrile,
2-amino-6-(4-fluorophenyl)-4-(2-furyl)nicotinonitrile,
2-amino-4-(3-fluorophenyl)-6-(3-hydroxyphenyl)nicotinonitrile,
6-amino-4-(3-fluorophenyl)-2,4'-bipyridine-5-carbonitrile,
6-amino-4-(2-fluorophenyl)-2,4'-bipyridine-5-carbonitrile,
2-amino-4-butyl-6-methylnicotinonitrile,
2-amino-6-methyl-4-propylnicotinonitrile,
2-amino-4-ethyl-6-methylnicotinonitrile, 2-amino-4,6-dimethylnicotinonitrile,
2-amino-4-[2-(hexyloxy)phenyl]-6,7-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,

2-amino-4-[2-(beta-D-glucopyranosyloxy)phenyl]-6,7-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
4-[2-(allyloxy)phenyl]-2-amino-6,7-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
methyl [2-(2-amino-3-cyano-6,7-dihydro-5H-pyrazolo[3,4-h]quinolin-4-yl)phenoxy]acetate,
2-amino-4-(2-ethoxyphenyl)-6,7-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
ethyl 4-[2-amino-3-cyano-6-(2-furyl)pyridin-4-yl]-1H-pyrrole-2-carboxylate,
2-amino-6-methylnicotinonitrile,
2-amino-6-(4-cyanophenyl)-4-(2-furyl)nicotinonitrile,
2-amino-6-(4-fluorobenzyl)-4-(2-furyl)nicotinonitrile,
2-amino-5-(4-fluorophenyl)-4-(2-furyl)-6-methylnicotinonitrile,
2-amino-4-(2-furyl)-6-(4-methoxyphenyl)nicotinonitrile,
2-amino-4-(2-methylphenyl)-5,6,7,8-tetrahydroquinoline-3-carbonitrile,
2-amino-4-(4-methoxyphenyl)-5,6,7,8-tetrahydroquinoline-3-carbonitrile,
2-amino-4-phenyl-5,6,7,8-tetrahydroquinoline-3-carbonitrile,
2-amino-6-(4-methoxyphenyl)-4-(2-methylphenyl)nicotinonitrile,
2-amino-4,6-bis(4-methoxyphenyl)nicotinonitrile,
2-amino-4-(3-chlorophenyl)-6-(4-methoxyphenyl)nicotinonitrile,
2-amino-4-(2-chlorophenyl)-6-(4-methoxyphenyl)nicotinonitrile,
2-amino-4-(2-furyl)-5,6,7,8-tetrahydro-1,6-naphthyridine-3-carbonitrile,
2-amino-4-(2-furyl)-6-(4-methylphenyl)nicotinonitrile,
2-amino-4-(2-furyl)-6-phenylnicotinonitrile,
6-amino-4-(2-furyl)-2,3'-bipyridine-5-carbonitrile,
2-amino-6-(1,3-benzodioxol-5-yl)-4-(2-furyl)nicotinonitrile,
2-amino-4-isoquinolin-4-yl-6-(4-methoxyphenyl)nicotinonitrile,
2-amino-4-(1-benzothien-3-yl)-6-(4-methoxyphenyl)nicotinonitrile,
2-amino-6-(4-methoxyphenyl)-4-thien-3-ylnicotinonitrile,
2-amino-4-(3-furyl)-6-(4-methoxyphenyl)nicotinonitrile,
2-amino-6-(4-methoxyphenyl)-4-(1H-pyrrol-2-yl)nicotinonitrile,
2-amino-4-(2-furyl)-6-(1H-pyrrol-2-yl)nicotinonitrile,

2'-amino-6'-(4-methoxyphenyl)-3,4'-bipyridine-3'-carbonitrile,
2-amino-4-[2-(trifluoromethoxy)phenyl]-6,7-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
2-amino-4-(2-furyl)-5H-thiochromeno[4,3-b]pyridine-3-carbonitrile,
2-amino-4-{4-[(2-cyanoethyl)(methyl)amino]phenyl}-6,7-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
2-amino-4-[2-(2-hydroxyethoxy)phenyl]-6,7-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
2-amino-4-(2-methylphenyl)-6,7-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
2-amino-4-[4-(dimethylamino)phenyl]-6,7-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
2-amino-4-(1H-indol-7-yl)-6,7-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
methyl 4-(2-amino-3-cyano-6,7-dihydro-5H-pyrazolo[3,4-h]quinolin-4-yl)benzoate,
methyl 2-(2-amino-3-cyano-6,7-dihydro-5H-pyrazolo[3,4-h]quinolin-4-yl)benzoate,
[2-(2-amino-3-cyano-6,7-dihydro-5H-pyrazolo[3,4-h]quinolin-4-yl)phenoxy]acetic acid,
2-amino-6-phenylnicotinonitrile,
2-amino-6-cyclohexylnicotinonitrile,
2-amino-4-(2-furyl)-6-(1-trityl-1H-pyrazol-4-yl)nicotinonitrile,
2-amino-4-(2-fluorophenyl)-6-(4-hydroxyphenyl)nicotinonitrile,
2,4-diamino-7,8-dihydroxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-8-hydroxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2-amino-7,8-dihydroxy-4-[(2-hydroxyethyl)amino]-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-7,8-dimethoxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2-amino-7,8-dihydroxy-4-(propylamino)-5H-chromeno[2,3-b]pyridine-3-carbonitrile,

2-amino-4-(ethylamino)-7,8-dihydroxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-9-hydroxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-9-fluoro-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-7-hydroxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-8-(2-hydroxyethoxy)-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
8,10-diamino-2,3-dihydro-11H-[1,4]dioxino[2',3':6,7]chromeno[2,3-b]pyridine-9-carbonitrile,
2,4,7-triamino-5H-chromeno[2,3-b]pyridine-3-carbonitrile
2,4-diamino-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-8-(2-ethoxyethoxy)-7-hydroxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-9-hydroxy-8-methoxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-6,8-dihydroxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-8-ethoxy-7-hydroxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-8-(2-ethoxyethoxy)-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-8-(2-aminoethoxy)-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-3-cyano-5H-chromeno[2,3-b]pyridine-7-carboxylic acid,
2,4-diamino-8,9-dihydroxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-8-(2-morpholin-4-ylethoxy)-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
[(2,4-diamino-3-cyano-5H-chromeno[2,3-b]pyridin-8-yl)oxy]acetic acid,
2,4-diamino-9-methoxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-8-(2-pyrrolidin-1-ylethoxy)-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2-amino-7,8-dimethoxy-4-(methylamino)-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-8-methoxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,

2,4-diamino-8-[2-(dimethylamino)ethoxy]-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4,7-triamino-9-methoxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2(2,4-diamino-3-cyano-8-methoxy-5H-chromeno[2,3-b]pyridin-5-yl)malononitrile,
2,4-diamino-7,8-di[2-(amino)ethoxy]-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-9-nitro-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2-amino-7,8-dimethoxy-4-[(4-methoxyphenyl)amino]-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-8-methoxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2(2,4-diamino-3-cyano-7-hydroxy-5H-chromeno[2,3-b]pyridin-5-yl)malononitrile,
2(2,4-diamino-3-cyano-7-bromo-5H-chromeno[2,3-b]pyridin-5-yl)malononitrile,
2-amino-8-ethoxy-4-(ethylamino)-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4,9-triamino-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4,7-triamino-5H-thiochromeno[2,3-b]pyridine-3-carbonitrile,
2-amino-7,8-dimethoxy-4-[(4-methoxyphenyl)amino]-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2(2,4-diamino-3-cyano-7-methoxy-5H-chromeno[2,3-b]pyridin-5-yl)malononitrile,
2,4-diamino-9-hydroxy-8-(piperidin-1-ylmethyl)-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
7,8-bis(allyloxy)-2,4-diamino-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2-amino-8-(2-ethoxyethoxy)-4-[(2-ethoxyethyl)amino]-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
tert-butyl {[2,4-diamino-7-(2-tert-butoxy-2-oxoethoxy)-3-cyano-5H-chromeno[2,3-b]pyridin-8-yl]oxy}acetate,
2-amino-4-[(2-aminoethyl)amino]-7,8-dimethoxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,

2(2,4-diamino-3-cyano-8-hydroxy-5H-chromeno[2,3-b]pyridin-5-yl)malononitrile,
2,4,7-triamino-5H-thiochromeno[2,3-b]pyridine-3-carbonitrile 10,10-dioxide,
2,4-diamino-7-bromo-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2-amino-7,8-dimethoxy-4-(propylamino)-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-7-hydroxy-5H-thiochromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-7-(dimethylamino)-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-7-methoxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2(2,4-diamino-3-cyano-9-methoxy-5H-chromeno[2,3-b]pyridin-5-yl)malononitrile,
2-amino-4-(benzylamino)-7,8-dimethoxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
8-(allyloxy)-2,4-diamino-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-9-fluoro-5H-thiochromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-7-methoxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-9-(2-pyrrolidin-1-ylethoxy)-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-7-nitro-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-10-methyl-5,10-dihydrobenzo[b]-1,8-naphthyridine-3-carbonitrile,
[(2,4-diamino-3-cyano-5H-chromeno[2,3-b]pyridin-9-yl)oxy]acetic acid,
2-amino-4-{[2-(dimethylamino)ethyl]amino}-7,8-dimethoxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-7-nitro-5H-thiochromeno[2,3-b]pyridine-3-carbonitrile 10,10-dioxide,
2,4-diamino-7-phenyl-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-7-chloro-9-methyl-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-7-fluoro-5H-thiochromeno[2,3-b]pyridine-3-carbonitrile 10,10-dioxide,
8-ethoxy-2,4-bis(ethylamino)-5H-chromeno[2,3-b]pyridine-3-carbonitrile,

2,4-diamino-5-(2-fluoro-phenyl)-8-methoxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-9-(2-hydroxyethoxy)-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-9-(2-aminoethoxy)-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2(2,4-diamino-3-cyano-7-chloro-5H-chromeno[2,3-b]pyridin-5-yl)malononitrile,
2,4-bis{[2-(dimethylamino)ethyl]amino}-7,8-dimethoxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2-amino-4-{[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl]amino}-7,8-dimethoxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-7-fluoro-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-7-bromo-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-9-(pyridin-4-ylmethoxy)-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-7-chloro-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-9-tert-butyl-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
ethyl 2,4-diamino-3-cyano-5H-chromeno[2,3-b]pyridine-9-carboxylate,
2,4-diamino-9-[2-(dimethylamino)ethoxy]-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-bis(butylamino)-7,8-dimethoxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2-amino-4-(butylamino)-7,8-dimethoxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
7,8-dimethoxy-2,4-bis(propylamino)-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-bis(ethylamino)-7,8-dimethoxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2-amino-4-(ethylamino)-7,8-dimethoxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-6,8-dimethoxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,

2,4-diamino-7-(trifluoromethoxy)-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-7-bromo-9-methoxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-9-methoxy-7-nitro-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
7,9-diamino-10H-[1,3]dioxolo[6,7]chromeno[2,3-b]pyridine-8-carbonitrile,
7,9-diamino-10H-[1,3]dioxolo[6,7]chromeno[2,3-b]pyridine-8-carbonitrile,
2,4-diamino-8-methyl-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
7,8-dimethoxy-2,4-bis[(2-methoxyethyl)amino]-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2-amino-7,8-dimethoxy-4-[(2-methoxyethyl)amino]-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2-amino-7,8-dimethoxy-4-[(2-pyrrolidin-1-ylethyl)amino]-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
7,8-dimethoxy-2,4-bis[(2-pyrrolidin-1-ylethyl)amino]-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-bis(glycinyl)-7,8-dimethoxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
N-(2-amino-3-cyano-7,8-dimethoxy-5H-chromeno[2,3-b]pyridin-4-yl)glycine,
2,4-diamino-3-cyano-5H-chromeno[2,3-b]pyridine-9-carboxylic acid,
2,4-diamino-6-methoxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-9-bromo-7-chloro-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-bis(ethylamino)-7,8-dihydroxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-6-bromo-9-methoxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-8-hydroxy-7,9-bis(piperidin-1-ylmethyl)-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-5-phenyl-8-hydroxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-5-(3-fluoro-phenyl)-8-methoxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,

2,4-diamino-9-hydroxy-6,8-bis(piperidin-1-ylmethyl)-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-7-bromo-8-methoxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-5-phenyl-8-methoxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-9-fluoro-5H-thiochromeno[2,3-b]pyridine-3-carbonitrile 10,10-dioxide,
2,4-diamino-7-nitro-5H-thiochromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-7-methoxy-5H-thiochromeno[2,3-b]pyridine-3-carbonitrile 10,10-dioxide,
2,4-diamino-7-methoxy-5H-thiochromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-5H-thiochromeno[2,3-b]pyridine-3-carbonitrile 10,10-dioxide,
2,4-diamino-5H-thiochromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-7-fluoro-5H-thiochromeno[2,3-b]pyridine-3-carbonitrile,
2-amino-7,9-dimethyl-5-oxo-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2-amino-7-isopropyl-5-oxo-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2-amino-7-ethyl-5-oxo-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2-amino-7-methyl-5-oxo-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2-amino-7-chloro-5-oxo-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2-amino-7-bromo-5-oxo-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2-amino-5-oxo-5H-chromeno[2,3-b]pyridine-3-carbonitrile, and
3-amino-5H-pyrido[3,4-b][1,4]benzothiazine-4-carbonitrile.

8. A method of inhibiting mitogen activated protein kinase-activated protein kinase-2 in a subject in need of such inhibition, the method comprising administering to the subject a compound, or a pharmaceutically acceptable salt thereof, the compound having the structure:



wherein:

G is selected from the group consisting of - O -, - S -, and -N-;

when G is -O-, R^{41} and R^{42} are absent;

when G is -S-, R^{41} and R^{42} are optionally absent, or are oxo;

when G is -N-, R^{41} is absent, and R^{42} is -H or C_1-C_4-alkyl;

R^1, R^2, R^{35}, R^{36}, R^{37}, R^{38}, R^{39}, and R^{40} each is independently selected from the group consisting of

hydrogen, hydroxy, amino, halo, nitro,

branched or unbranched C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 alkoxy, hydroxy C_1-C_6 alkyl, hydroxy C_1-C_6 alkoxy, C_1-C_6 alkoxy C_1-C_6 alkoxy, C_1-C_6 alkoxy C_1-C_6 alkyl, C_2-C_6 alkenoxy,

branched or unbranched amino C_1-C_6 alkyl, diamino C_2-C_6 alkyl, C_1-C_6 alkylamino C_1-C_6 alkyl, C_1-C_6 alkylamino, di-(C_1-C_6 alkyl)amino, C_1-C_4 alkoxyarylamino, C_1-C_4 alkoxyalkylamino, amino C_1-C_6 alkoxy, di-(C_1-C_4 alkylamino, C_2-C_6 alkoxy, di-(C_1-C_6 alkyl)amino C_1-C_6 alkyl, C_1-C_6 alkylamino C_1-C_6 alkoxy, halo C_1-C_6 alkoxy, dihalo C_1-C_6 alkoxy, trihalo C_1-C_6 alkoxy, cyano C_1-C_6 alkyl, dicyano C_1-C_6 alkyl, cyano C_1-C_6 alkoxy, dicyano C_1-C_6 alkoxy, carbamyl C_1-C_4 alkoxy, heterocyclyl C_1-C_4 alkoxy, heteroaryl C_1-C_4 alkoxy, sulfo, sulfamyl, C_1-C_4 alkylaminosulfonyl, hydroxy C_1-C_4 alkylaminosulfonyl, di-(C_1-C_4 alkyl)aminosulfonyl, C_1-C_4 alkylthio, C_1-C_4 alkylsulfonyl, C_1-C_4 alkylsulfinyl,

aryl, aryl C_1-C_6 alkyl, heterocyclyl C_1-C_6 alkyl, heteroaryl C_1-C_6 alkyl, heterocyclyl C_1-C_6 alkoxl, heteroaryl C_1-C_6 alkoxy, aryl C_1-C_6 alkoxy, where the aryl ring can be substituted or unsubstituted, and, if substituted,

the substituent group is selected from one or more of the group consisting of C_1-C_6 alkyl, halo, amino, and C_1-C_6 alkoxy,

substituted or unsubstituted C_3-C_6 cyclyl, C_3-C_6 heterocyclyl, and, if substituted, the substituent group is selected from one or more of the group consisting of C_1-C_6 alkyl, C_1-C_6 alkoxy, halo, amino, and where the C_3-C_6 heterocyclyl ring contains O, S, or N,

branched or unbranched C_1-C_6 alkoxycarbonyl C_1-C_6 alkoxy, and

carboxy, carboxy C_1-C_6 alkoxy, carboxy C_1-C_6 alkyl, hydroxy C_1-C_4 alkoxycarbonyl, C_1-C_4 alkoxycarbonyl,

where R^{38} and R^{39} are such that they optionally join to form a ring system of the type selected from

 , and 

9. The method according to claim 8, wherein the compound is one having the structure:



wherein:

G is selected from the group consisting of - O -, - S -, and -N-;

when G is -O-, R^{41} and R^{42} are absent;

when G is -S-, R^{41} and R^{42} are optionally absent, or are oxo;

when G is -N-, R^{41} is absent, and R^{42} is -H or C_1-C_4-alkyl;

R^1 is selected from the group consisting of hydrogen, branched or unbranched alkyl, alkenyl, alkynyl, alkoxy, alkylaryl, arylalkyl, carboxy, carboxyalkyl, hydroxyalkyl, alkylcarboxy, aryl, amino, aminoalkyl, alkylamino, halo, alkylaminoalkyl, alkoxy, alkoxyalkyl, monocyclyl, bicyclyl, polycyclyl, and heterocyclyl;

R^2 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxyalkyl, alkylaryl, arylalkyl, alkoxyaryl, aminoalkyl, alkylaminoalkyl, arylaminoalkyl, alkoxyalkyl, alkylcarboxy, and carboxyalkyl;

R^{35} is selected from the group consisting of hydrogen, dicyanoalkyl, and substituted or unsubstituted heterocyclyl and cyclyl, where substituents, if any, comprise halo moieties;

R^{36} is selected from the group consisting of hydrogen, dicyanoalkyl, and substituted or unsubstituted heterocyclyl and cyclyl, where substituents, if any, comprise halo moieties;

R^{37} is selected from the group consisting of hydrogen, alkoxy, halo, alkyl, alkenyl, alkylyl, arylalkyl, or alkylaryl;

R^{38} is selected from the group consisting of hydrogen, hydroxy, alkoxy, alkyl, alkenyl, alkynyl, amino, alkylamino, arylamino, alkylaminoalkyl, carboxy, aminoalkoxy, halo, alkylcarboxyalkyl, alkylamino, aminoalkyl, nitro, aryl, arylalkyl, alkylaryl, or arylamino;

R^{39} is selected from the group consisting of hydrogen, hydroxy, alkoxy, alkenoxy, hydroxyalkoxy, alkoxyalkoxy, aminoalkoxy, heterocyclylalkyl, heterocyclylalkoxy, carboxyalkoxy, alkylaminoalkoxy, and alkylcarboxyalkoxy;

where the R^{38} and R^{39} groups optionally join to form a six membered heterocyclic ring; and

R^{40} is selected from the group consisting of hydrogen, hydroxy, halo, nitro, amino, alkyl, alkoxy, heterocyclylalkoxy, carboxyalkoxy, pyrrolidylethoxy, carboxymethoxy, hydroxyalkoxy, aminoalkoxy, alkylcarboxy, alkylaminoalkyl, carboxy, and heterocyclylalkyl.

10. A method of inhibiting mitogen activated protein kinase-activated protein kinase-2 in a subject in need of such inhibition, the method comprising administering to the subject a compound, or a pharmaceutically acceptable salt thereof, the compound having the structure:



wherein:

G is selected from the group consisting of -O-, -S-, and -N-;

when G is -O-, R^{41} and R^{42} are absent;

when G is -S-, R^{41} and R^{42} are optionally absent, or are oxo;

when G is -N-, R^{41} is absent, and R^{42} is -H or $-CH_3$;

R^1 is selected from the group consisting of hydrogen, ethyl, dimethylaminoethyl, butyl, propyl, methoxyethyl, tetramethylaminoethyl, and carboxymethyl;

R^2 is selected from the group consisting of hydrogen, hydroxyethyl, propyl, ethyl, methyl, 4-methoxyphenyl, ethoxyethyl, aminoethyl, phenylmethyl, dimethylaminoethyl, phthaloaminoethyl, butyl, methoxyethyl, tetramethylaminoethyl, and carboxymethyl;

R^{35} is selected from the group consisting of hydrogen, dicyanomethyl, 2-fluorophenyl, phenyl, and 3-fluorophenyl.

R^{36} is selected from the group consisting of hydrogen, dicyanomethyl, 2-fluorophenyl, phenyl, and 3-fluorophenyl;

R^{37} is selected from the group consisting of hydrogen, hydroxy, methoxy, bromo, and 2-pyridomethyl;

R^{38} is selected from the group consisting of hydrogen, hydroxy, methoxy, amino, carboxy, diaminoethoxy, bromo, propoxy,

isobutylcarboxymethoxy, dimethylamino, nitro, phenyl, chloro, pyridylmethyl, and fluoro;

R^{39} is selected from the group consisting of hydrogen, hydroxy, methoxy, hydroxyethoxy, ethoxyethoxy, ethoxy, aminoethoxy, morpholinoethoxy, carboxymethoxy, *N*-pyrrolidylethoxy, dimethylaminoethoxy, pyridylmethyl, 2-propenoxy, and isobutylcarboxymethoxy, where the R^{38} and R^{39} groups optionally join to form a six membered heterocyclic ring; and

R^{40} is selected from the group consisting of hydrogen, hydroxy, fluoro, methoxy, nitro, amino, pyrrolidylethoxy, carboxymethoxy, methyl, hydroxyethoxy, aminoethoxy, 4-pyridylmethoxy, isobutyl, ethylcarboxy, dimethylaminoethoxy, carboxy, bromo, and pyrridylmethyl.

11. The method according to claim 9, wherein the compound is one wherein:

G is selected from the group consisting of -O- and -S-;

when G is -O-, R^{41} and R^{42} are absent;

when G is -S-, R^{41} and R^{42} are optionally absent, or are oxo;

R^1 is selected from the group consisting of hydrogen, and C_1-C_2 alky;

R^2 is selected from the group consisting of hydrogen, C_1-C_3 alkyl, hydroxy C_1-C_2 alkyl, C_1-C_2 alkoxyphenyl, C_1-C_2 alkoxy C_1-C_2 alkyl, amino C_1-C_2 alkyl, phenyl C_1-C_2 alkyl, and di C_1-C_2 alkylamino C_1-C_2 alkyl;

R^{35} and R^{36} are each independently selected from the group consisting of hydrogen, dicyano C_1-C_2 alkyl, and halophenyl;

R^{37} is selected from the group consisting of hydrogen, and hydroxy;

R^{38} is selected from the group consisting of hydrogen, hydroxy, C_1 - C_3 alkoxy, amino, nitro, carboxy, diamino C_1 - C_2 alkoxy, halo, propenoxy, iso C_3 - C_4 alkylcarboxy C_1 - C_2 alkoxy, di C_1 - C_2 alkylamino, and phenyl;

R^{39} is selected from the group consisting of hydrogen, hydroxy, C_1 - C_3 alkoxy, hydroxy C_1 - C_2 alkoxy, C_1 - C_2 alkoxy C_1 - C_2 alkoxy, amino C_1 - C_2 alkoxy, morpholino C_1 - C_2 alkoxy, carboxyl C_1 - C_2 alkoxy, pyrrolidyl

C_1 - C_2 alkoxy, di C_1 - C_2 alkylamino C_1 - C_2 alkoxy, pyrrolidyl C_1 - C_2 alkyl, iso C_3 - C_4 alkylcarboxy C_1 - C_2 alkoxy, and 2-propenoxy,

where the R^{38} and R^{39} groups can join to form a six membered heterocyclic ring; and

R^{40} is selected from the group consisting of hydrogen, hydroxy, halo, C_1-C_2 alkyl, C_1-C_2 alkoxy, nitro, amino, pyrrolidyl C_1-C_2 alkoxy, carboxy C_1-C_2 alkoxy, hydroxy C_1-C_2 alkoxy, and amino C_1-C_2 alkoxy.

12. The method according to claim 10, wherein the compound is one wherein:

G is selected from the group consisting of -O- and -S-;

when G is -O-, R^{41} and R^{42} are absent;

when G is -S-, R^{41} and R^{42} are optionally absent, or are oxo;

R^1 is hydrogen;

R^2 is selected from the group consisting of hydrogen, C_1 - C_3 alkyl, hydroxy C_1 - C_2 alkyl, C_1 - C_2 alkoxyphenyl, C_1 - C_2 alkoxy C_1 - C_2 alkyl, amino C_1 - C_2 alkyl, phenyl C_1 - C_2 alkyl, and di C_1 - C_2 alkylamino C_1 - C_2 alkyl;

R^{35} and R^{36} are each independently selected from the group consisting of hydrogen, and dicyano C_1 - C_2 alkyl.

R^{37} is selected from the group consisting of hydrogen, and hydroxy;

R^{38} is selected from the group consisting of hydrogen, hydroxy, C_1-C_2 alkoxy, amino, nitro, carboxy, diamino C_1-C_2 alkoxy, halo, 2-propenoxy, iso C_3-C_4 alkylcarboxy C_1-C_2 alkoxy, di C_1-C_2 alkylamino, and phenyl;

R^{39} is selected from the group consisting of hydrogen, hydroxy, C_1 - C_2 alkoxy, hydroxy C_1-C_2 alkoxy, C_1-C_2 alkoxy C_1-C_2 alkoxy, amino C_1-C_2 alkoxy, morpholino C_1-C_2 alkoxy, carboxyl C_1-C_2 alkoxy, pyrrolidyl C_1-C_2 alkoxy, di C_1-C_2 alkylamino C_1-C_2 alkoxy, pyrrolidyl C_1-C_2 alkyl, iso C_3-C_4 alkylcarboxy C_1-C_2 alkoxy, and 2-propenoxy;

wherein the R^{38} and R^{39} groups optionally join to form a six membered heterocyclic ring; and

R^{40} is selected from the group consisting of hydrogen, hydroxy, halo, C_1-C_2 alkoxy, nitro, amino, pyrrolidyl C_1-C_2 alkoxy, and carboxy C_1-C_2 alkoxy.

13. The method according to claim 10, wherein the compound is one wherein:

G is selected from the group consisting of -O- and -S-;

when G is -O-, R^{41} and R^{42} are absent;

when G is -S-, R^{41} and R^{42} are optionally absent, or are oxo;

R^1 is hydrogen;

R^2 is selected from the group consisting of hydrogen, C_1-C_3 alkyl, hydroxy C_1-C_2 alkyl, C_1-C_2 alkoxyphenyl, C_1-C_2 alkoxy C_1-C_2 alkyl, amino C_1-C_2 alkyl, and phenyl C_1-C_2 alkyl;

R^{35} and R^{36} are each independently selected from the group consisting of hydrogen, and dicyano C_1-C_2 alkyl.

R^{37} is selected from the group consisting of hydrogen, and hydroxy;

R^{38} is selected from the group consisting of hydrogen, hydroxy, C_1-C_2 alkoxy, amino, carboxy, diamino C_1-C_2 alkoxy, halo, 2-propenoxy, iso C_3-C_4 alkylcarboxy C_1-C_2 alkoxy, and di C_1-C_2 alkylamino;

R^{39} is selected from the group consisting of hydrogen, hydroxy, C_1-C_2 alkoxy, hydroxy C_1-C_2 alkoxy, C_1-C_2 alkoxy C_1-C_2 alkoxy, amino C_1-C_2 alkoxy, morpholino C_1-C_2 alkoxy, carboxyl C_1-C_2 alkoxy, pyrrolidyl C_1-C_2 alkoxy, di C_1-C_2 alkylamino C_1-C_2 alkoxy, pyrrolidyl C_1-C_2 alkyl, iso C_3-C_4 alkylcarboxy C_1-C_2 alkoxy, and 2-propenoxy;

where the R^{38} and R^{39} groups optionally join to form a six membered heterocyclic ring; and

R^{40} is selected from the group consisting of hydrogen, hydroxy, halo, C_1-C_2 alkoxy, nitro, amino, and pyrrolidyl C_1-C_2 alkoxy.

14. The method according to claim 10, wherein the compound is one wherein:

G is selected from the group consisting of -O- and -S-;

when G is -O-, R^{41} and R^{42} are absent;

when G is -S-, R^{41} and R^{42} are optionally absent, or are oxo;

R^1 is hydrogen;

R^2 is selected from the group consisting of hydrogen, C_1-C_3 alkyl, hydroxy C_1-C_2 alkyl, C_1-C_2 alkoxyphenyl, C_1-C_2 alkoxy C_1-C_2 alkyl, and amino C_1-C_2 alkyl;

R^{35} and R^{36} are each independently selected from the group consisting of hydrogen, and dicyanoethyl;

R^{37} is selected from the group consisting of hydrogen, and hydroxy;

R^{38} is selected from the group consisting of hydrogen, hydroxy, C_1-C_2 alkoxy, amino, carboxy, diamino C_1-C_2 alkoxy, halo, $_2$-propenoxy, iso C_3-C_4 alkylcarboxy C_1-C_2 alkoxy, and di C_1-C_2 alkylamino;

R^{39} is selected from the group consisting of hydrogen, hydroxy, C_1-C_2 alkoxy, hydroxy C_1-C_2 alkoxy, C_1-C_2 alkoxy C_1-C_2 alkoxy, amino C_1-C_2 alkoxy, morpholino C_1-C_2 alkoxy, carboxyl C_1-C_2 alkoxy, pyrrolidyl C_1-C_2 alkoxy, di C_1-C_2 alkylamino C_1-C_2 alkoxy, pyrrolidyl C_1-C_2 alkyl, iso C_3-C_4 alkylcarboxy C_1-C_2 alkoxy, and 2-propenoxy;

where the R^{38} and R^{39} groups optionally join to form a six membered heterocyclic ring; and

R^{40} is selected from the group consisting of hydrogen, hydroxy, halo, methoxy, nitro, and amino.

15. The method according to claim 1, wherein the aminocyanopyridine MK-2 inhibiting compound comprises at least one compound that is selected from the group consisting of:

2-amino-4-(2-fluorophenyl)-6,8-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,

2-amino-4-(2-furyl)-6,7-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,

2-amino-4-(2,3-difluorophenyl)-6,7-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,

8-amino-6-(2-furyl)-4,5-dihydro-1H-pyrazolo[4,3-h]quinoline-7-carbonitrile,

2-amino-3-cyano-4-(2-furyl)-5,6-dihydrobenzo[h]quinoline-8-carboxylic acid,

4-[2-amino-3-cyano-6-(2-furyl)pyridin-4-yl]-1H-pyrrole-2-carboxamide,

2-amino-4-phenyl-6,8-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,

2-amino-6-(2-furyl)-4-(1-methyl-1H-imidazol-4-yl)nicotinonitrile,
8-amino-6-(2-furyl)-4,5-dihydro-1H-pyrazolo[4,3-h]quinoline-7-carbonitrile,
2-amino-4-(2-furyl)-8-hydroxy-5,6-dihydrobenzo[h]quinoline-3-carbonitrile,
2-amino-4-(2,6-difluorophenyl)-6,7-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
2-amino-6-(4-hydroxyphenyl)-4-(1H-imidazol-5-yl)nicotinonitrile,
2-amino-4-(2-fluorophenyl)-6-(2-furyl)nicotinonitrile, 2-amino-4-(2-fluorophenyl)-6-(2-furyl)nicotinonitrile,
2-amino-4-(2-fluorophenyl)-5,6-dihydrobenzo[h]quinoline-3-carbonitrile,
4-[6-amino-5-cyano-4-(2-furyl)pyridin-2-yl]benzoic acid,
2-amino-6-(2-furyl)-4-(1H-imidazol-5-yl)nicotinonitrile,
2-amino-4-(2-furyl)-6-(1H-pyrazol-3-yl)nicotinonitrile,
2-amino-3-cyano-4-(4H-1,2,4-triazol-3-yl)-5,6-dihydrobenzo[h]quinoline-8-carboxylic acid,
2-amino-6-(3-hydroxyphenyl)-4-(1H-imidazol-5-yl)nicotinonitrile,
2-amino-6-(2-furyl)-4-(1H-imidazol-4-yl)nicotinonitrile,
2-amino-4-(2,4-difluorophenyl)-6,7-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile, 4,6-diamino-2-(trifluoromethyl)-2,3-dihydrofuro[2,3-b]pyridine-5-carbonitrile,
2-amino-4-(2-furyl)-6,8-dihydro-5H-pyrrolo[3,4-h]quinoline-3-carbonitrile,
4-[6-amino-5-cyano-4-(2-fluorophenyl)pyridin-2-yl]benzoic acid,
2-amino-4-(2-furyl)-5,6-dihydro-1,8-phenanthroline-3-carbonitrile,
2-amino-6-(3,4-dihydroxyphenyl)-4-(2-fluorophenyl)nicotinonitrile,
2-amino-4-(1-methyl-1H-imidazol-4-yl)-6-phenylnicotinonitrile,
2-amino-4-(2-furyl)-6-(1H-pyrazol-3-yl)nicotinonitrile,
4-[6-amino-5-cyano-4-(1H-imidazol-5-yl)pyridin-2-yl]benzoic acid,
2-amino-4-(3-fluorophenyl)-6,8-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
2-amino-6-(3,4-dihydroxyphenyl)-4-(2-fluorophenyl)nicotinonitrile,
N-{4-[6-amino-5-cyano-4-(2-furyl)pyridin-2-yl]phenyl}methanesulfonamide,
2-amino-4-(2-furyl)-6,7-dihydro-5H-pyrrolo[2,3-h]quinoline-3-carbonitrile,
2-amino-4-(1H-imidazol-5-yl)-6-phenylnicotinonitrile,

2-amino-4-(2-furyl)-5,6-dihydrobenzo[h]quinoline-3-carbonitrile,
2-amino-4-(1H-imidazol-5-yl)-6-(4-methoxyphenyl)nicotinonitrile,
2-amino-6-(3-chlorophenyl)-4-(1H-imidazol-5-yl)nicotinonitrile,
2-amino-4-(2-furyl)-6-(1H-pyrazol-4-yl)nicotinonitrile,
2-amino-4-(4-methoxyphenyl)-6,7-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
2-amino-4-(2,5-difluorophenyl)-6,7-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
2-amino-4-(4-fluorophenyl)-6,8-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
2-amino-4-(4H-1,2,4-triazol-3-yl)-5,6-dihydrobenzo[h]quinoline-3-carbonitrile,
4,6-diamino-2-(chloromethyl)-2,3-dihydrofuro[2,3-b]pyridine-5-carbonitrile,
2-amino-4-(1H-imidazol-4-yl)-6-phenylnicotinonitrile,
4-[6-amino-5-cyano-4-(2-furyl)pyridin-2-yl]benzenesulfonamide,
4-[6-amino-5-cyano-4-(2-furyl)pyridin-2-yl]phenylboronic acid,
2-amino-6-(4-methoxyphenyl)-4-(4H-1,2,4-triazol-3-yl)nicotinonitrile,
2-amino-4-(2-fluorophenyl)-6-(3-furyl)nicotinonitrile,
2-amino-6-(2-furyl)-4-(methylthio)nicotinonitrile,
2-amino-4-(2-fluorophenyl)-6-(3-hydroxyphenyl)nicotinonitrile,
8-amino-6-(2-furyl)-4,5-dihydro-2H-pyrazolo[4,3-h]quinoline-7-carbonitrile,
2-amino-4-(2-bromophenyl)-6-(2-furyl)nicotinonitrile,
2-amino-4-(2-fluorophenyl)-6-(4-hydroxyphenyl)nicotinonitrile,
2-amino-4-phenyl-6-thien-2-ylnicotinonitrile,
2-amino-4-(3-methoxyphenyl)-6,7-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
2-amino-4-(2-furyl)-7-methyl-6,7-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
2-amino-4-(2-fluorophenyl)-6-(1H-pyrrol-2-yl)nicotinonitrile,
2-amino-4-(2-furyl)-5-methyl-6,8-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
2-amino-4-(2-furyl)-6-(1-methyl-1H-pyrrol-3-yl)nicotinonitrile,

3-amino-5,6,7,8-tetrahydroisoquinoline-4-carbonitrile,
N-[4-(2-amino-3-cyano-6,7-dihydro-5H-pyrazolo[3,4-h]quinolin-4-yl)phenyl]acetamide,
6-amino-4-[(4-methoxyphenyl)amino]-2-(trifluoromethyl)-2,3-dihydrofuro[2,3-b]pyridine-5-carbonitrile,
4-[6-amino-5-cyano-4-(2-furyl)pyridin-2-yl]-*N*-(tert-butyl)benzenesulfonamide,
4,6-diamino-2-ethyl-2,3-dihydrofuro[2,3-b]pyridine-5-carbonitrile,
6-amino-4-(2-furyl)-2,4'-bipyridine-5-carbonitrile, 2,4-diamino-6-(methylthio)nicotinonitrile,
3-(2-amino-3-cyano-6,7-dihydro-5H-pyrazolo[3,4-h]quinolin-4-yl)benzoic acid,
2-amino-6-(4-chlorophenyl)-4-(1H-imidazol-5-yl)nicotinonitrile,
2-amino-4-(1,3-benzodioxol-4-yl)-6,7-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile, 4,6-diamino-2-methyl-2,3-dihydrofuro[2,3-b]pyridine-5-carbonitrile,
2-amino-4-(1H-imidazol-5-yl)-6-[4-(methylsulfonyl)phenyl]nicotinonitrile,
2,4-diaminoquinoline-3-carbonitrile,
2,8-diamino-4-(2-furyl)-5,6-dihydrobenzo[h]quinoline-3-carbonitrile,
2-amino-4,6-di(2-furyl)nicotinonitrile,
4,6-diamino-2-butyl-2,3-dihydrofuro[2,3-b]pyridine-5-carbonitrile,
ethyl 4-[6-amino-5-cyano-4-(1H-imidazol-5-yl)pyridin-2-yl]benzoate,
2,4-diamino-6-methoxynicotinonitrile,
2-amino-4-methylnicotinonitrile,
2-amino-4-(4-cyanophenyl)-6,7-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
2-amino-4-cyclopropyl-6-methylnicotinonitrile,
2-amino-4-(2-furyl)-6-(1-methyl-1H-pyrrol-2-yl)nicotinonitrile,
2-amino-4-(2-chlorophenyl)-6,7-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
2-amino-6-(2-furyl)-4-(4-phenoxyphenyl)nicotinonitrile,

2-amino-4-pyridin-3-yl-6,8-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
2-amino-6-{[2-(4-chlorophenyl)-2-oxoethyl]thio}-4-(2-furyl)pyridine-3,5-dicarbonitrile,
4-[2-amino-3-cyano-6-(2-furyl)pyridin-4-yl]phenylboronic acid,
2-amino-6-(3-chlorophenyl)-4-(1H-imidazol-4-yl)nicotinonitrile,
4-(6-amino-5-cyano-4-phenylpyridin-2-yl)-*N*-(tert-butyl)benzenesulfonamide,
2-amino-4-methoxynicotinonitrile,
4-[2-amino-3-cyano-6-(2-furyl)pyridin-4-yl]benzoic acid,
4,6-diamino-2-[(4-methoxyphenoxy)methyl]-2,3-dihydrofuro[2,3-b]pyridine-5-carbonitrile, 2-amino-4-(2-fluorophenyl)-6-(4-methoxyphenyl)nicotinonitrile,
4-[6-amino-5-cyano-4-(2-fluorophenyl)pyridin-2-yl]-*N*-(tert-butyl)benzenesulfonamide, (2,4-diamino-3-cyano-5H-chromeno[2,3-b]pyridin-9-yl)oxy]acetic acid,
3-Pyridinecarbonitrile, 2-Amino-4-Methylm
2-amino-6-(2-furyl)nicotinonitrile,
2-amino-4-(2-furyl)-6-(3-hydroxyphenyl)nicotinonitrile,
4-[6-amino-5-cyano-4-(2-furyl)pyridin-2-yl]benzamide,
2-amino-4-(2-furyl)-7-hydroxy-5,6-dihydrobenzo[h]quinoline-3-carbonitrile,
2-amino-4-(2-furyl)-6-(1H-indol-3-yl)nicotinonitrile,
2-amino-4-pyridin-4-yl-6,8-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
2-amino-4-(3-fluorophenyl)-6-(4-hydroxyphenyl)nicotinonitrile,
2-amino-4-[2-(difluoromethoxy)phenyl]-6,7-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
2-amino-4-(2-furyl)-6-thien-3-ylnicotinonitrile,
2-amino-4-(3-fluorophenyl)-6-(4-methoxyphenyl)nicotinonitrile,
2-[2-amino-3-cyano-6-(2-furyl)pyridin-4-yl]phenylboronic acid,
2,4-diamino-6-propylpyridine-3,5-dicarbonitrile,
2,4-diamino-7,8-dihydroxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,

2,4-diamino-8-hydroxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2-amino-7,8-dihydroxy-4-[(2-hydroxyethyl)amino]-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-7,8-dimethoxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2-amino-7,8-dihydroxy-4-(propylamino)-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2-amino-4-(ethylamino)-7,8-dihydroxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-9-hydroxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-9-fluoro-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-7-hydroxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-8-(2-hydroxyethoxy)-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
8,10-diamino-2,3-dihydro-11H-[1,4]dioxino[2',3':6,7]chromeno[2,3-b]pyridine-9-carbonitrile,
2,4,7-triamino-5H-chromeno[2,3-b]pyridine-3-carbonitrile
2,4-diamino-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-8-(2-ethoxyethoxy)-7-hydroxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile, 2,4-diamino-9-hydroxy-8-methoxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-6,8-dihydroxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-8-ethoxy-7-hydroxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-8-(2-ethoxyethoxy)-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-8-(2-aminoethoxy)-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-3-cyano-5H-chromeno[2,3-b]pyridine-7-carboxylic acid,
2,4-diamino-8,9-dihydroxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-8-(2-morpholin-4-ylethoxy)-5H-chromeno[2,3-b]pyridine-3-carbonitrile, [(2,4-diamino-3-cyano-5H-chromeno[2,3-b]pyridin-8-yl)oxy]acetic acid,
2,4-diamino-9-methoxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,

2,4-diamino-8-(2-pyrrolidin-1-ylethoxy)-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2-amino-7,8-dimethoxy-4-(methylamino)-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-8-methoxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-8-[2-(dimethylamino)ethoxy]-5H-chromeno[2,3-b]pyridine-3-carbonitrile, 2,4,7-triamino-9-methoxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2(2,4-diamino-3-cyano-8-methoxy-5H-chromeno[2,3-b]pyridin-5-yl)malononitrile,
2,4-diamino-7,8-di[2-(amino)ethoxy]-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-9-nitro-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2-amino-7,8-dimethoxy-4-[(4-methoxyphenyl)amino]-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-8-methoxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2(2,4-diamino-3-cyano-7-hydroxy-5H-chromeno[2,3-b]pyridin-5-yl)malononitrile,
2(2,4-diamino-3-cyano-7-bromo-5H-chromeno[2,3-b]pyridin-5-yl)malononitrile,
2-amino-8-ethoxy-4-(ethylamino)-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4,9-triamino-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4,7-triamino-5H-thiochromeno[2,3-b]pyridine-3-carbonitrile,
2-amino-7,8-dimethoxy-4-[(4-methoxyphenyl)amino]-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2(2,4-diamino-3-cyano-7-methoxy-5H-chromeno[2,3-b]pyridin-5-yl)malononitrile,
2,4-diamino-9-hydroxy-8-(piperidin-1-ylmethyl)-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
7,8-bis(allyloxy)-2,4-diamino-5H-chromeno[2,3-b]pyridine-3-carbonitrile,

2-amino-8-(2-ethoxyethoxy)-4-[(2-ethoxyethyl)amino]-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
tert-butyl {[2,4-diamino-7-(2-tert-butoxy-2-oxoethoxy)-3-cyano-5H-chromeno[2,3-b]pyridin-8-yl]oxy}acetate,
2-amino-4-[(2-aminoethyl)amino]-7,8-dimethoxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2(2,4-diamino-3-cyano-8-hydroxy-5H-chromeno[2,3-b]pyridin-5-yl)malononitrile,
2,4,7-triamino-5H-thiochromeno[2,3-b]pyridine-3-carbonitrile 10,10-dioxide,
2,4-diamino-7-bromo-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2-amino-7,8-dimethoxy-4-(propylamino)-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-7-hydroxy-5H-thiochromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-7-(dimethylamino)-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-7-methoxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2(2,4-diamino-3-cyano-9-methoxy-5H-chromeno[2,3-b]pyridin-5-yl)malononitrile,
2-amino-4-(benzylamino)-7,8-dimethoxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
8-(allyloxy)-2,4-diamino-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-9-fluoro-5H-thiochromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-7-methoxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-9-(2-pyrrolidin-1-ylethoxy)-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-7-nitro-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2;4-diamino-10-methyl-5,10-dihydrobenzo[b]-1,8-naphthyridine-3-carbonitrile,
[(2,4-diamino-3-cyano-5H-chromeno[2,3-b]pyridin-9-yl)oxy]acetic acid,
2-amino-4-{[2-(dimethylamino)ethyl]amino}-7,8-dimethoxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,

2,4-diamino-7-nitro-5H-thiochromeno[2,3-b]pyridine-3-carbonitrile 10,10-dioxide,
2,4-diamino-7-phenyl-5H-chromeno[2,3-b]pyridine-3-carbonitrile, and prodrugs, salts, tautomers, and combinations thereof.

16. The method according to claim 1, wherein the aminocyanopyridine MK-2 inhibiting compound comprises at least one compound that is selected from the group consisting of:
2-amino-4-(2-fluorophenyl)-6,8-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
2-amino-4-(2-furyl)-6,7-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
2-amino-4-(2,3-difluorophenyl)-6,7-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
8-amino-6-(2-furyl)-4,5-dihydro-1H-pyrazolo[4,3-h]quinoline-7-carbonitrile,
2-amino-3-cyano-4-(2-furyl)-5,6-dihydrobenzo[h]quinoline-8-carboxylic acid,
4-[2-amino-3-cyano-6-(2-furyl)pyridin-4-yl]-1H-pyrrole-2-carboxamide,
2-amino-4-phenyl-6,8-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
2-amino-6-(2-furyl)-4-(1-methyl-1H-imidazol-4-yl)nicotinonitrile,
8-amino-6-(2-furyl)-4,5-dihydro-1H-pyrazolo[4,3-h]quinoline-7-carbonitrile,
2-amino-4-(2-furyl)-8-hydroxy-5,6-dihydrobenzo[h]quinoline-3-carbonitrile,
2-amino-4-(2,6-difluorophenyl)-6,7-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
2-amino-6-(4-hydroxyphenyl)-4-(1H-imidazol-5-yl)nicotinonitrile,
2-amino-4-(2-fluorophenyl)-6-(2-furyl)nicotinonitrile, 2-amino-4-(2-fluorophenyl)-6-(2-furyl)nicotinonitrile,
2-amino-4-(2-fluorophenyl)-5,6-dihydrobenzo[h]quinoline-3-carbonitrile,
4-[6-amino-5-cyano-4-(2-furyl)pyridin-2-yl]benzoic acid,
2-amino-6-(2-furyl)-4-(1H-imidazol-5-yl)nicotinonitrile,
2-amino-4-(2-furyl)-6-(1H-pyrazol-3-yl)nicotinonitrile,
2-amino-3-cyano-4-(4H-1,2,4-triazol-3-yl)-5,6-dihydrobenzo[h]quinoline-8-carboxylic acid,
2-amino-6-(3-hydroxyphenyl)-4-(1H-imidazol-5-yl)nicotinonitrile,

2-amino-6-(2-furyl)-4-(1H-imidazol-4-yl)nicotinonitrile,
2-amino-4-(2,4-difluorophenyl)-6,7-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile, 4,6-diamino-2-(trifluoromethyl)-2,3-dihydrofuro[2,3-b]pyridine-5-carbonitrile,
2-amino-4-(2-furyl)-6,8-dihydro-5H-pyrrolo[3,4-h]quinoline-3-carbonitrile,
4-[6-amino-5-cyano-4-(2-fluorophenyl)pyridin-2-yl]benzoic acid,
2-amino-4-(2-furyl)-5,6-dihydro-1,8-phenanthroline-3-carbonitrile,
2-amino-6-(3,4-dihydroxyphenyl)-4-(2-fluorophenyl)nicotinonitrile,
2-amino-4-(1-methyl-1H-imidazol-4-yl)-6-phenylnicotinonitrile,
2-amino-4-(2-furyl)-6-(1H-pyrazol-3-yl)nicotinonitrile,
4-[6-amino-5-cyano-4-(1H-imidazol-5-yl)pyridin-2-yl]benzoic acid,
2-amino-4-(3-fluorophenyl)-6,8-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
2-amino-6-(3,4-dihydroxyphenyl)-4-(2-fluorophenyl)nicotinonitrile,
N-{4-[6-amino-5-cyano-4-(2-furyl)pyridin-2-yl]phenyl}methanesulfonamide,
2-amino-4-(2-furyl)-6,7-dihydro-5H-pyrrolo[2,3-h]quinoline-3-carbonitrile,
2-amino-4-(1H-imidazol-5-yl)-6-phenylnicotinonitrile,
2-amino-4-(2-furyl)-5,6-dihydrobenzo[h]quinoline-3-carbonitrile,
2-amino-4-(1H-imidazol-5-yl)-6-(4-methoxyphenyl)nicotinonitrile,
2,4-diamino-7,8-dihydroxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-8-hydroxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2-amino-7,8-dihydroxy-4-[(2-hydroxyethyl)amino]-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-7,8-dimethoxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2-amino-7,8-dihydroxy-4-(propylamino)-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2-amino-4-(ethylamino)-7,8-dihydroxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-9-hydroxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-9-fluoro-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-7-hydroxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,

2,4-diamino-8-(2-hydroxyethoxy)-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
8,10-diamino-2,3-dihydro-11H-[1,4]dioxino[2',3':6,7]chromeno[2,3-b]pyridine-9-carbonitrile,
2,4,7-triamino-5H-chromeno[2,3-b]pyridine-3-carbonitrile
2,4-diamino-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-8-(2-ethoxyethoxy)-7-hydroxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile, 2,4-diamino-9-hydroxy-8-methoxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-6,8-dihydroxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-8-ethoxy-7-hydroxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-8-(2-ethoxyethoxy)-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-8-(2-aminoethoxy)-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-3-cyano-5H-chromeno[2,3-b]pyridine-7-carboxylic acid,
2,4-diamino-8,9-dihydroxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-8-(2-morpholin-4-ylethoxy)-5H-chromeno[2,3-b]pyridine-3-carbonitrile, [(2,4-diamino-3-cyano-5H-chromeno[2,3-b]pyridin-8-yl)oxy]acetic acid,
2,4-diamino-9-methoxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-8-(2-pyrrolidin-1-ylethoxy)-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2-amino-7,8-dimethoxy-4-(methylamino)-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-8-methoxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-8-[2-(dimethylamino)ethoxy]-5H-chromeno[2,3-b]pyridine-3-carbonitrile, 2,4,7-triamino-9-methoxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2(2,4-diamino-3-cyano-8-methoxy-5H-chromeno[2,3-b]pyridin-5-yl)malononitrile,
2,4-diamino-7,8-di[2-(amino)ethoxy]-5H-chromeno[2,3-b]pyridine-3-carbonitrile,

2,4-diamino-9-nitro-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2-amino-7,8-dimethoxy-4-[(4-methoxyphenyl)amino]-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-8-methoxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2(2,4-diamino-3-cyano-7-hydroxy-5H-chromeno[2,3-b]pyridin-5-yl)malononitrile,
2(2,4-diamino-3-cyano-7-bromo-5H-chromeno[2,3-b]pyridin-5-yl)malononitrile,
2-amino-8-ethoxy-4-(ethylamino)-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4,9-triamino-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4,7-triamino-5H-thiochromeno[2,3-b]pyridine-3-carbonitrile,
2-amino-7,8-dimethoxy-4-[(4-methoxyphenyl)amino]-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2(2,4-diamino-3-cyano-7-methoxy-5H-chromeno[2,3-b]pyridin-5-yl)malononitrile,
2,4-diamino-9-hydroxy-8-(piperidin-1-ylmethyl)-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
7,8-bis(allyloxy)-2,4-diamino-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2-amino-8-(2-ethoxyethoxy)-4-[(2-ethoxyethyl)amino]-5H-chromeno[2,3-b]pyridine-3-carbonitrile, and
prodrugs, salts, tautomers, and combinations thereof.

17. The method according to claim 1, wherein the aminocyanopyridine MK-2 inhibiting compound is selected from the group consisting of:
2-amino-4-(2-fluorophenyl)-6,8-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
2-amino-4-(2-furyl)-6,7-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
2-amino-4-(2,3-difluorophenyl)-6,7-dihydro-5H-pyrazolo[3,4-h]quinoline-3-carbonitrile,
8-amino-6-(2-furyl)-4,5-dihydro-1H-pyrazolo[4,3-h]quinoline-7-carbonitrile,
2,4-diamino-7,8-dihydroxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,

2,4-diamino-8-hydroxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2-amino-7,8-dihydroxy-4-[(2-hydroxyethyl)amino]-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-7,8-dimethoxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2-amino-7,8-dihydroxy-4-(propylamino)-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2-amino-4-(ethylamino)-7,8-dihydroxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-9-hydroxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-9-fluoro-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-7-hydroxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-8-(2-hydroxyethoxy)-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
8,10-diamino-2,3-dihydro-11H-[1,4]dioxino[2',3':6,7]chromeno[2,3-b]pyridine-9-carbonitrile,
2,4,7-triamino-5H-chromeno[2,3-b]pyridine-3-carbonitrile
2,4-diamino-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-8-(2-ethoxyethoxy)-7-hydroxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile, 2,4-diamino-9-hydroxy-8-methoxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-6,8-dihydroxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-8-ethoxy-7-hydroxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-8-(2-ethoxyethoxy)-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-8-(2-aminoethoxy)-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-3-cyano-5H-chromeno[2,3-b]pyridine-7-carboxylic acid,
2,4-diamino-8,9-dihydroxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-8-(2-morpholin-4-ylethoxy)-5H-chromeno[2,3-b]pyridine-3-carbonitrile, [(2,4-diamino-3-cyano-5H-chromeno[2,3-b]pyridin-8-yl)oxy]acetic acid,
2,4-diamino-9-methoxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,

2,4-diamino-8-(2-pyrrolidin-1-ylethoxy)-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2-amino-7,8-dimethoxy-4-(methylamino)-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-8-methoxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2,4-diamino-8-[2-(dimethylamino)ethoxy]-5H-chromeno[2,3-b]pyridine-3-carbonitrile, 2,4,7-triamino-9-methoxy-5H-chromeno[2,3-b]pyridine-3-carbonitrile,
2(2,4-diamino-3-cyano-8-methoxy-5H-chromeno[2,3-b]pyridin-5-yl)malononitrile, and
prodrugs, salts, tautomers, and combinations thereof.

18. A method of preventing or treating a TNFα mediated disease or disorder in a subject in need of such prevention or treatment, the method comprising administering to the subject an effective amount of an aminocyanopyridine MK-2 inhibiting compound.

19. The method according to claim 18, wherein the aminocyanopyridine MK-2 inhibiting compound is one having the formula:



wherein:

R^1 is selected from the group consisting of -H, methyl, ethyl, propyl, butyl, -(CH_2)COOH, phenyl, pyridyl, dimethylaminoethyl, methoxyethyl, tetramethylaminoethyl, carboxymethyl, and phenylacetyl;

R^2 is selected from the group consisting of -H, methyl, ethyl, propyl, butyl, amino, phenyl, methoxy, carboxy, carboxymethyl, hydroxyethylamino, propylamino, ethylamino, methylamino, methoxyethyl,

ethoxyethylamino, aminoethylamino, benzylamino, dimethylaminoethylamino, phthaloaminoethyl, fluorophenyl, difluorophenyl, chlorophenyl, bromophenyl, furyl, carbamylpyrryl, methyl-1,3-isodiazoyl, 1,3-isodiazoyl, 1,3,4-triazoyl, methoxyphenyl, -S(CH_3), tetramethylaminoethyl, acetylaminophenyl, methoxyphenylamino, carboxyphenyl, carboxy-3-isopyrryl, cyanophenyl, cyclopropyl, phenoxyphenyl, pyridyl, dihydroxybromophenyl, difluoromethoxyphenyl, trifluoromethylphenyl, trifluoromethylfluorophenyl, hydroxyphenyl, methylaminomethyl, methylaminoethyl, thiophyl, pyrryl, aminomethyl,



R^3 is selected from the group consisting of -H, methyl, ethyl, propyl, isopropyl, cyano, aminomethyl, phenyl, fluorophenyl, and amino;

wherein the R^2 and R^3 groups are such that they optionally join to form a ring system selected from:



R^4 is selected from the group consisting of -H, methyl, ethyl, propyl, hydroxy, furyl, methylfuryl, methylimidazolyl, phenyl, hydroxyphenyl, carboxyphenyl, pyrazolyl, hydroxy, dihydroxyphenyl, methoxyphenyl,

chlorophenyl, bromophenyl, fluorophenyl, dichlorophenyl, dihydroxyborophenyl, thienyl, pyrryl, *N*-methylpyrryl, pyridyl, methylthio, methylsulfonylphenyl, carboethoxyphenyl, methoxy, carbamylphenyl, mercapto, *N*-isoimidazoylphenyl, isopropyl, amino, hydroxynaphthyl, thiazoyl, carboxymethylphenyl, trifluoromethylphenyl, methylphenyl, cyanophenyl, dimethylphenyl, fluorobenzhydryl, methoxyfuryl, aminosulfonylphenyl,



wherein the R^3 and R^4 groups are such that they optionally join to form a ring system selected from:


R7
R6
R8
R9
R10
D
E
G
R11
R12

,


R14
R13
R15
R16
R17
R18
R20
R19

,


R22
R21
R24
R23
D
R25
E
R26
G
R27
R28
R29
R30

,


R31
R32
R33
R34

,


R37
R36
R35
R38
D
R39
E
G
R40
R41
R42

,


R43
R44
R45
R46

,


R50
R49
R48
R47
R51
R52
R53
R54
D

,


R56
R57
R55
R58
D
E
R59
G
R60
R62
R61

,


R63
R64
R65
R66
R70
R667
R69
R68

, and


R72
R71
D
R73
E
R74
G
R76
R75

;

D, E and G are each independently selected from the group consisting of carbon, oxygen, sulfur, and nitrogen;

R^5 is selected from the group consisting of -H, and C_1-C_5 alkyl; and

wherein the R^1 and R^5 groups can join to form a pyridylidene ring;

R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}, R^{23}, R^{24}, R^{25}, R^{26}, R^{27}, R^{28}, R^{29}, R^{30}, R^{31}, R^{32}, R^{33}, R^{34}, R^{35}, R^{36}, R^{37}, R^{38}, R^{39}, R^{40}, R^{41}, R^{42}, R^{43}, R^{44}, R^{45}, R^{46}, R^{47}, R^{48}, R^{49}, R^{50}, R^{51}, R^{52}, R^{53}, R^{54}, R^{55}, R^{56}, R^{57}, R^{58}, R^{59}, R^{60}, R^{61}, R^{62}, R^{63}, R^{64}, R^{65}, R^{66}, R^{67}, R^{68}, R^{69}, R^{70} R^{71}, R^{72}, R^{73}, R^{74}, R^{75}, and R^{76} are each optionally present and are each independently selected from the group consisting of - H, methyl, ethyl, propyl, butyl, isobutyl, amino, nitro, hydroxy, methoxy, ethoxy, propoxy, 2-propenoxy, oxo, carboxy, bromo, chloro, fluoro, trifluoromethyl, chloromethyl, hydroxymethyl, dicyanomethyl, 2-fluorophenyl, 3-fluorophenyl, hydroxyethoxy, ethoxyethoxy, -(CH_2)-O-(C_6H_4)-O-(CH_3), carboxymethoxy, isopropylcarboxymethoxy, isobutylcarboxymethoxy, methylamino, dimethylamino, aminoethoxy, diaminoethoxy, dimethylaminoethoxy, cyanomethoxymethyl, 2-propenoxymethyl, methoxymethyl, isopropoxymethyl, ethoxymethyl, -(CH_2)-O-(CF_2)-CHF_2, isobutoxymethyl, benzoyl, phenyl, *N*-morpholinyl, morpholinylethoxy, pyrrolidylethoxy, *N*-pyrrolidylethoxy, oxo, ethylcarboxy, carboxymethyl - ethyl ester, pyridylmethyl, 4-pyridylmethoxy, 2-pyridylmethyl, and -COO-CH_2-CH_3; and

wherein R^{38} and R^{39} are such that they optionally join to form a ring system of the type selected from:


, and


20. The method according to claim 18, wherein the aminocyanopyridine MK-2 inhibiting compound is one having the structure:



wherein:

G is selected from the group consisting of - O -, - S -, and -N-;

when G is -O-, R^{41} and R^{42} are absent;

when G is -S-, R^{41} and R^{42} are optionally absent, or are oxo;

when G is -N-, R^{41} is absent, and R^{42} is -H or C_1-C_4-alkyl;

R^1 is selected from the group consisting of hydrogen, branched or unbranched alkyl, alkenyl, alkynyl, alkoxy, alkylaryl, arylalkyl, carboxy, carboxyalkyl, hydroxyalkyl, alkylcarboxy, aryl, amino, aminoalkyl, alkylamino, halo, alkylaminoalkyl, alkoxy, alkoxyalkyl, monocyclyl, bicyclyl, polycyclyl, and heterocyclyl;

R^2 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxyalkyl, alkylaryl, arylalkyl, alkoxyaryl, aminoalkyl, alkylaminoalkyl, arylaminoalkyl, alkoxyalkyl, alkylcarboxy, and carboxyalkyl;

R^{35} is selected from the group consisting of hydrogen, dicyanoalkyl, and substituted or unsubstituted heterocyclyl and cyclyl, where substituents, if any, comprise halo moieties;

R^{36} is selected from the group consisting of hydrogen, dicyanoalkyl, and substituted or unsubstituted heterocyclyl and cyclyl, where substituents, if any, comprise halo moieties;

R^{37} is selected from the group consisting of hydrogen, alkoxy, halo, alkyl, alkenyl, alkylyl, arylalkyl, or alkylaryl;

R^{38} is selected from the group consisting of hydrogen, hydroxy, alkoxy, alkyl, alkenyl, alkynyl, amino, alkylamino, arylamino,

alkylaminoalkyl, carboxy, aminoalkoxy, halo, alkylcarboxyalkyl, alkylamino, aminoalkyl, nitro, aryl, arylalkyl, alkylaryl, or arylamino;

R^{39} is selected from the group consisting of hydrogen, hydroxy, alkoxy, alkenoxy, hydroxyalkoxy, alkoxyalkoxy, aminoalkoxy, heterocyclylalkyl, heterocyclylalkoxy, carboxyalkoxy, alkylaminoalkoxy, and alkylcarboxyalkoxy;

where the R^{38} and R^{39} groups optionally join to form a six membered heterocyclic ring; and

R^{40} is selected from the group consisting of hydrogen, hydroxy, halo, nitro, amino, alkyl, alkoxy, heterocyclylalkoxy, carboxyalkoxy, pyrrolidylethoxy, carboxymethoxy, hydroxyalkoxy, aminoalkoxy, alkylcarboxy, alkylaminoalkyl, carboxy, and heterocyclylalkyl.

21. The method according to claim 18, wherein the subject is a mammal.

22. The method according to claim 21, wherein the subject is a human.

23. The method according to claim 22, wherein the TNFα mediated disease or disorder is selected from the group consisting of: arthritis, rheumatoid arthritis, spondyloarthopathies, gouty arthritis, osteoarthritis, systemic lupus erythematosus, juvenile arthritis, asthma, bronchitis, menstrual cramps, tendinitis, bursitis, connective tissue injuries or disorders, skin related conditions, psoriasis, eczema, burns, dermatitis, gastrointestinal conditions, inflammatory bowel disease, gastric ulcer, gastric varices, Crohn's disease, gastritis, irritable bowel syndrome, ulcerative colitis, cancer, colorectal cancer, herpes simplex infections, HIV, pulmonary edema, kidney stones, minor injuries, wound healing, vaginitis, candidiasis, lumbar spondylanhrosis, lumbar spondylarthrosis, vascular diseases, migraine headaches, sinus headaches, tension headaches, dental pain, periarteritis nodosa, thyroiditis, aplastic anemia, Hodgkin's disease, sclerodoma, rheumatic fever, type I diabetes, myasthenia gravis, multiple sclerosis, sarcoidosis, nephrotic syndrome, Behcet's syndrome, polymyositis, gingivitis, hypersensitivity, swelling occurring after injury,

myocardial ischemia, ophthalmic diseases, retinitis, retinopathies, conjunctivitis, uveitis, ocular photophobia, acute injury to the eye tissue, pulmonary inflammation, viral infections, cystic fibrosis, central nervous system disorders, cortical dementias, and Alzheimer's disease.

24. The method according to claim 18, wherein the subject is administered an effective amount of the aminocyanopyridine MK-2 inhibiting compound.

25. The method according to claim 24, wherein the effective amount comprises an amount within a range of from about 0.1 mg/kg/day to about 150 mg/kg/day.

26. The method according to claim 25, wherein the effective amount comprises an amount within a range of from about 0.1 mg/kg/day to about 10 mg/kg/day.

27. The method according to claim 18, wherein the aminocyanopyridine MK-2 inhibiting compound provides a TNFα release IC_{50} values of below 200 μM in an *in vitro* cell assay.

28. The method according to claim 18, wherein the aminocyanopyridine MK-2 inhibiting compound provides a TNFα release IC_{50} values of below 1 μM in an *in vitro* cell assay.

29. The method according to claim 18, wherein the aminocyanopyridine MK-2 inhibiting compound provides a degree of inhibition of TNFα in a rat LPS assay of at least about 25%.

30. The method according to claim 18, wherein the aminocyanopyridine MK-2 inhibiting compound provides a degree of inhibition of TNFα in a rat LPS assay of above 80%.

31. The method according to claim 18, wherein the aminocyanopyridine MK-2 inhibiting compound provides an MK-2 inhibition IC_{50} value of below 200 μM.

32. The method according to claim 18, wherein the aminocyanopyridine MK-2 inhibiting compound provides an MK-2 inhibition IC_{50} value of below 1 μM.